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Cerebral cavernous malformation (CCM), or cavernous angioma, is a common
disease that can occur sporadically or familially with autosomal dominant inheritance. 
CCMs are vascular malformations, predominantly in the brain, consisting of dilated, thin-
walled, blood-filled caverns.  These lesions can lead to headaches, seizures, focal
neurological deficits, and hemorrhagic stroke, but the only available treatment is surgical
resection.  Familial CCM has been linked to three genes: KRIT1, CCM2, or PDCD10. 
These genes encode structurally unrelated proteins of poorly understood function, but the
three are hypothesized to work as a complex .1
Generation of an animal model that faithfully recapitulates CCM disease would
greatly benefit the study of the natural history and pathophysiology of CCM and the
search for therapeutics.  In this dissertation, I demonstrate that Pdcd10 and CCM2 signal
through distinct pathways, but that loss of heterozygosity is a common genetic
mechanism by which both genes lead to CCM disease.  I show that Ccm2 acts to suppress
the activity of the small GTPase RhoA, whereas Pdcd10 acts through the GCKIII family
of kinases.  Studies of knockout mice demonstrate that Ccm2 and Pdcd10 serve essential,
but different, functions in the endothelium during development.  I also examined Pdcd10
function using the fruitfly Drosophila melanogaster, which has a homolog for PDCD10
but not KRIT1 and CCM2.  These studies revealed that Pdcd10 regulates lumen formation
in the Drosophila tracheal system and genetically interacts with GCKIII, distinguishing it
from Ccm2 and indicating that Pdcd10 can function independently of the other CCM
genes.  Despite these differences in function, loss of heterozygosity at either locus results
in the highly penetrant formation of dilated, vascular caverns in mice that phenocopy
human CCM histologically and radiologically.
My studies led to the surprising conclusion that the CCM proteins do not share a
common signaling mechanism.  The distinct pathways, however, lead to a common
pathology by the genetic mechanism of loss of heterozygosity.  My work has also begun
to elucidate the underlying biochemistry behind CCM, which may suggest potential
therapies.  The establishment of an animal model with highly penetrant disease, similar to
human disease, is a powerful first step in developing these therapies.
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CHAPTER 1
RECENT INSIGHTS INTO CEREBRAL CAVERNOUS
MALFORMATIONS: ANIMAL MODELS OF CCM
AND THE HUMAN PHENOTYPE
The following chapter was reprinted with permission from Blackwell Publishing. 
In addition to myself, the other authors were Dean Li, Michel Berg, and Kevin
Whitehead.  It was originally published in FEBS Journal, 2010 Mar;277(5):1076-83,
Epub 2010 Jan 22.  This manuscript was one of a three-part review series and focuses on
the human phenotype of cerebral cavernous malformation disease and animal models.
2MINIREVIEW
Recent insights into cerebral cavernous malformations:
animal models of CCM and the human phenotype
Aubrey C. Chan1, Dean Y. Li1,2, Michel J. Berg3 and Kevin J. Whitehead1,2
1 Molecular Medicine Program, University of Utah, Salt Lake City, UT, USA
2 Division of Cardiology, University of Utah, Salt Lake City, UT, USA
3 Department of Neurology, University of Rochester Medical Center, NY, USA
Introduction
Cerebral cavernous malformation (CCM) is a common
vascular disease consisting of clusters of dilated, thin-
walled vessels lacking smooth muscle support and
prone to hemorrhage. They are found in 1 in 200–250
individuals in the general population [1,2]. Although
named for their predilection for the central nervous
system (CNS), CCMs are also found in the retina, skin
and other organs [3]. CCMs can be sporadic or famil-
ial, with the familial form manifesting with earlier
onset and a higher number of malformations. The
familial form is linked to three genes, KRIT1
(KREV1 ⁄RAP1A interaction trapped-1 also known as
CCM1) [4,5], CCM2 (also known as OSM or Osmo-
sensing scaffold for MEKK3) [6–8] and PDCD10 (Pro-
grammed cell death 10, also known as CCM3) [9]. The
genetics of cavernous malformations is reviewed by
Riant et al. [10].
The proteins encoded by these three genes are struc-
turally unrelated and lack catalytic domains. Consider-
able progress has been made characterizing the
interaction partners and the signaling pathways of the
CCM proteins. The biochemistry of these pathways is
reviewed by Faurobert & Albiges-Rizo [11]. Although
such basic mechanistic studies are necessary to come
to a more complete understanding of the underlying
cellular processes that lead to disease, these studies are
difﬁcult to interpret without the context of in vivo cor-
relation. Furthermore, these studies have been per-
formed in a variety of cell types, both primary cultures
and established laboratory cell lines. An understanding
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Cerebral cavernous malformations are common vascular lesions of the cen-
tral nervous system that predispose to seizures, focal neurologic deﬁcits
and potentially fatal hemorrhagic stroke. Human genetic studies have iden-
tiﬁed three genes associated with the disease and biochemical studies of
these proteins have identiﬁed interaction partners and possible signaling
pathways. A variety of animal models of CCM have been described to help
translate the cellular and biochemical insights into a better understanding
of disease mechanism. In this minireview, we discuss the contributions of
animal models to our growing understanding of the biology of cavernous
malformations, including the elucidation of the cellular context of CCM
protein actions and the in vivo conﬁrmation of abnormal endothelial cell–
cell interactions. Challenges and progress towards developing a faithful
model of CCM biology are reviewed.
Abbreviations
CCM, cerebral cavernous malformations; CNS, central nervous system; MEKK3, mitogen-activated protein kinase kinase kinase.
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3of the relevant cell types in the formation of vascular
malformations in CCM is needed to put these studies
into a physiological context. Ultimately, the goal of
all research into CCM is to understand the basic
processes that have been disrupted, resulting in the
vascular malformation. Between observational and
genetic studies in humans and biochemical and cellular
studies at the bench lies a gap. This minireview
explores the contributions of animal models to bridge
this gap and add to our growing understanding of
CCM pathophysiology.
Conservation of CCM genes
The genes responsible for CCM are very well
conserved among different organisms (Fig. 1). These
genes are found not only in mammals, ﬁsh and other
vertebrates, but are also found in much more simple
and primitive organisms that lack a closed circulatory
system, such as Caenorhabditis elegans. The presence
of these genes in genetically tractable organisms has
allowed the development of numerous experimental
animal models, as discussed below.
Human phenotype
Although humans are generally not considered in the
category of animal models of disease, one can view the
ﬁeld of human genetics as probing a vast natural
mutagenesis screen involving billions of individual
organisms. As in any mutagenesis screen, the impor-
tant information on genotype must be coupled with a
detailed characterization of phenotype. All other ani-
mal models are relevant to disease to the degree that
they help us further understand the human phenotype.
Recent investigations have further reﬁned our under-
standing of this phenotype, and bear reviewing in this
manuscript.
In human CCM disease, the lesions exhibit a number
of characteristic features; these features will serve as
guideposts on the road to developing animal models of
CCM disease. Classically, a CCM consists of a cluster
of dilated blood vessels [12,13]. Each vessel in the clus-
ter is grossly dilated, earning the name of a cavern; each
vessel is lined only with a single layer of endothelium,
with the absence of normal vascular support cells, such
as smooth muscle cells. To be histologically classiﬁed as
a CCM, the lesion must contain multiple such vessels
adjacent to each other (Fig. 2). Grossly, this cluster
gives the lesion an appearance likened to a raspberry. In
addition, no brain parenchyma occurs in between the
vessels. Single dilated vessels, called capillary telangiec-
tasias, are not CCMs, although it has been hypothesized
that the disease progresses from a single capillary telan-
giectasia that blossoms into a multivessel CCM [13].
Functionally, the lesion vessels are subject to subclinical
bleeding, because hemosiderin, a breakdown product of
blood, is found in the brain tissues surrounding CCM
lesions [14]. Although CCMs have been clinically asso-
ciated as occurring with developmental venous malfor-
mations [15], it has been shown that these two types of
malformations are not linked genetically [16], and
familial cases of CCM are not generally associated
with venous malformations. Although these clinical
features deﬁne CCMs for physicians, little is known
about the cellular mechanisms that underlie and result
in such characteristics. These mechanisms are what
must be discovered, using either animal models or by
deeper study of human CCM patients.
Fig. 1. Conservation of CCM proteins across species. Similarity
scores were generated for the three CCM proteins in comparison
with human protein sequences (KRIT1, accession number
AAH98442; CCM2, accession number AAH16832; PDCD10, acces-
sion number NP_665859). Protein sequences or predicted protein
sequences for a variety of vertebrate and nonvertebrate species
were included if similarity was detected by BLASTp algorithm
across a full-length protein sequence. Blank fields represent spe-
cies for which an orthologous gene has yet to be identified in avail-
able databases. All three proteins are well conserved across
species, and are found in nonvertebrate species. Conservation is
particularly strong for PDCD10, the smallest of the three proteins.
Note that Pdcd10 has been duplicated in the zebrafish genome; the
two proteins are denoted (a) and (b). C. elegans, Caenorhabd-
itis elegans.
A. C. Chan et al. CCM animal models
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4One aspect of disease discovered in humans is that
CCMs are associated with an inﬂammatory response.
CCM lesions harbor a variety of immune cells [17],
and oligoclonal banding of IgG has been observed in
the CCM tissue [18]. What is still not known, however,
is whether this inﬂammatory response is a secondary
reaction to antigens exposed by the defective blood–
brain barrier of a CCM [19] or if inﬂammatory action
is part of the mechanism of pathogenesis leading to
formation of aberrant blood vessels. It is intriguing
that the mitogen-activated protein kinase kinase kinase
MEKK3 plays a key role in immune signaling [20],
and CCM2 protein has been shown to function as a
scaffold for MEKK3 in response to stress [6]. The
ﬁnding of immune involvement in CCM illustrates the
complexity of the disease; CCM is a vascular disease
localized mainly to neural tissues with an additional
immune component. The involvement of multiple cell
and tissue types raise the question of where the CCM
genes primarily function, and in which cell type their
loss leads to pathogenesis of disease.
Aside from the question of tissue speciﬁcity of CCM
gene function, another important question of disease
pathogenesis is that of a triggering event – what events
on a molecular, cellular or physiological level lead to
the formation of these isolated malformations? A clue
comes from studying patients with sporadic CCM and
those with familial CCM. People with an inherited
form of CCM have a larger number of lesions and
more frequent sequellae, such as seizure and hemor-
rhage. These features are reminiscent of the cancer ret-
inoblastoma, which led to the Knudson ‘two-hit’
hypothesis. Similarly, a two-hit hypothesis has been
proposed for the pathogenesis of CCM, in which an
inherited mutant allele is a silent, but predisposing hit,
and a second mutation acquired during life leads to a
disease phenotype. The data supporting this hypothesis
have been reviewed by Riant et al. [10] in an accompa-
nying minireview. In addition to genetic and epigenetic
events leading to CCM, these studies do not explore
physiologic stressors as potential disease triggers in the
heterozygous patient. For example, serum levels of the
angiogenic vascular endothelial growth factor have
been correlated with disease progression in case reports
[21,22].
Recent cell biology observations, supported by data
from mice, call to mind an important observational
study [19]. Using detailed ultrastructural examination
of surgically excised CCM specimens, the investigators
observed abnormal endothelial cell junctions from the
cavernous malformation. An important component of
the normal blood–brain barrier, tight junctions form
between endothelial cells and can be observed by elec-
tron microscopy. Although the cavernous malforma-
tion was found in the CNS where such tight junctions
are the rule, the investigators observed numerous
regions with impaired or deﬁcient tight junctions
between adjacent endothelial cells. These areas of junc-
tional breakdown were associated with hemosiderin
pigment as functional evidence that junction break-
down was associated with pathologic vascular leak,
one of the deﬁning features of CCMs.
Zebrafish
Hailed for its transparency and genetic tractability, a
signiﬁcant body of work has been carried out in zebra-
ﬁsh to determine the functions of the CCM genes.
Initial results were described for santa (san, the zebraﬁsh
orthologue of KRIT1) and valentine (vtn, the zebraﬁsh
A
B
Fig. 2. Histology of CCM. Masson trichrome stain of surgically
excised cavernous malformation. (A) Low-magnification view of
CCM and surrounding brain. Hyalinized caverns of varying size are
observed, surrounded by a rim of collagen deposits (blue). The adja-
cent brain shows evidence of gliosis (red). (B) Higher magnification
view of boxed area. The caverns are lined by a single layer of endo-
thelium (arrowheads) without smooth muscle support. Rather than
smooth muscle cells or pericytes, a hyalinized rim of collagen sur-
rounds the caverns (asterisks). Brown hemosiderin deposits are
observed in the surrounding gliotic brain tissue (arrows).
CCM animal models A. C. Chan et al.
1078 FEBS Journal 277 (2010) 1076–1083 ª 2010 The Authors Journal compilation ª 2010 FEBS
5orthologue of CCM2). Zebraﬁsh with loss-of-function
mutations in san or vtn share a common phenotype
with ﬁsh lacking heart of glass (heg). Although muta-
tions in the human orthologue of heart of glass
(HEG1) have not been identiﬁed in patients with
CCM, this gene has been shown to be functionally and
genetically related to santa and valentine.
Heg is a single-pass transmembrane protein. Zebra-
ﬁsh with a nonsense heg mutation exhibit a dilated
heart phenotype. The myocardium proliferates to a
normal number of cells, but instead of building into
concentric layers to form the walls of the heart, the
myocardial cells form into a single layer, resulting in a
dilated, thin-walled heart whose structure is reminis-
cent of a CCM vessel. Heg has two soluble splice vari-
ants in addition to the transmembrane isoform, but it
is the transmembrane isoform that is essential in car-
diac patterning. Although the defect is one of myocar-
dial patterning, heg is expressed in the endocardial
cells, indicating that this cell layer signals to the myo-
cardium via Heg [23].
Interestingly, ﬁsh with nonsense mutations in san
and vtn were later shown to exhibit the same pheno-
type as the heg mutant ﬁsh – that of the dilated heart
covered by a single layer of myocardium. The similar-
ity of the phenotype in these nonsense alleles suggested
that these three proteins share a common developmen-
tal function. In addition, co-morpholino experiments
demonstrated synergy among the three genes, putting
them into a common genetic pathway [24]. Another
group reﬁned the characterization of the santa and val-
entine phenotypes using different mutant alleles.
Focusing on the vasculature instead of the heart, they
found that these ﬁsh developed dilated, thin-walled
vessels that failed to form lumens. The dilated, thin-
walled, closed vessels, like the dilated, thin-walled
heart of these ﬁsh, are very reminiscent of human
CCM vessels and the closed vessels seen in CCM
knockout mice (see below). This dilation was attrib-
uted to abnormal endothelial cell spreading, a poten-
tial mechanistic insight into CCM pathogenesis. Of
note, these abnormal vessels were able to be rescued
by the transplantation of endothelial cells from wild-
type ﬁsh, again hinting that the endothelial cell is the
cell type that most needs the function of the CCM
proteins [25]. Later work also showed that loss of heg
or vtn via morpholino knockdown resulted in non-
patent vessels that patterned normally, similar to the
phenotypes seen in the Krit1 and Ccm2 knockout mice
(see below) [26]. Most recently, it has been shown that
a deletion mutation of pdcd10 (ccm3), which is dupli-
cated in the zebraﬁsh genome, results in the same
developmental defects as mutations in santa and
valentine [27], making the zebraﬁsh the ﬁrst non-
human model organism to link all three CCM genes
phenotypically. Speciﬁcally, these defects are caused by
the loss of Ccm3 interaction with the kinases ser-
ine ⁄ threonine kinase 25 (STK25) and mammalian ster-
ile twenty-like 4 (MST4), giving a hint to the signaling
pathway in which Ccm3 belongs, as both STK25 and
MST4 belong to a family of kinases that are thought
to act upstream of the mitogen-activated protein kinas-
es (see the accompanying minireview [11] on the bio-
chemical interactions of the CCM proteins).
Furthering the pursuit of genetic interactions,
co-morpholino experiments were performed to examine
the interactions between the CCM genes and rap1b, a
Ras family small GTPase known to regulate cell
junctions [28] and notable as being closely related
to RAP1A, the binding partner bait originally used to
identify KRIT1 [29]. Knockdown of rap1b via mor-
pholino resulted in defective endothelial cell junctions
and intracerebral hemorrhage in the ﬁsh, reminiscent
of both the slow, unpredictable blood leak and the
frank hemorrhage associated with CCMs [30]. The
dose of rap1b morpholino was then titrated down so
that the hemorrhage phenotype was seen in only a
small percentage of ﬁsh. Combining this low dose of
rap1b morpholino with a similarly low dose of san
morpholino resulted in a synergistic increase in both
the intracerebral hemorrhage phenotype of rap1b and
the cardiac developmental phenotype of san.
The zebraﬁsh experiments demonstrate the role of
the CCM genes in cardiac and vascular development;
the genetic tractability of the ﬁsh also provided a pow-
erful way to discover genetic interactions between the
CCM proteins and other proteins such as rap1b and
the previously unknown heg. A mystery remains as to
why HEG1 mutations are not found in humans with
CCMs. The synergistic effects of low-dose knockdown
of the CCM genes and their partners imply that a sim-
ilar mechanism may be responsible for pathogenesis in
humans; however, as previously stated, such polygenic
effects have yet to be identiﬁed in human tissue
samples.
Mouse
Mice have long been favored as a model organism for
laboratory studies and are the closest relative to
humans commonly used in genetic studies. Knockout
mice lacking Krit1 [31] and Ccm2 [26,32–34] have been
generated and described. Although an experimental
model of CCM lesions in the CNS was desired, neither
mice with heterozygous knockout of Krit1 nor Ccm2
develop CNS vascular lesions with any useful fre-
A. C. Chan et al. CCM animal models
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6quency [26,31–34]. Although disappointing, this lack
of faithful disease modeling has generally been the case
for most mouse genotype equivalents of human disease
[35–38].
An important role for mouse models of genetic dis-
ease is to identify essential roles for protein function
in vivo, especially in development where the proof of
essential function is often embryonic lethality in com-
plete knockouts. Indeed, mice lacking either Krit1 or
Ccm2 die in mid-gestation with vascular defects at the
same developmental stage, and with a similar pheno-
type [26,31,33,34]. The complete loss of Krit1 or Ccm2
results in vascular defects with a failure to connect the
developing heart to the developing aorta with a func-
tioning, patent ﬁrst branchial arch artery. The associ-
ated rostral portions of the aorta are similarly
narrowed (Fig. 3). As a result, circulation is not estab-
lished as expected at E8.5 [33], and developmental
arrest and death ensue. Prior to developmental arrest,
cardiac and neural development proceeds normally.
Cavernous malformations are vascular lesions that
form predominantly in the CNS. The basis for this
anatomic predisposition is uncertain, but one possibil-
ity suggested by the abundant neuronal expression of
the CCM genes [32,39–42] is a mechanism by which
there is impaired signaling from neuronal cells to the
endothelium, with a primary defect in the neuronal
cell. Alternatively, the defect may lie primarily in endo-
thelial cells, and the CNS selectivity of the disease
could be a result of a unique sensitivity of the CNS
vasculature to CCM gene function. To address these
possibilities, mice with tissue-speciﬁc deletions of Ccm2
using the Cre–Lox inducible recombination system
have been generated and described. Two separate
ﬂoxed Ccm2 alleles were generated by different research
groups [33,34]. Using Cre recombinase driven by the
Tie2 promoter to direct recombination in endothelial
cells, both groups found an absolute requirement for
Ccm2 in the endothelium during development. The
neuronal expression of Ccm2 was not required for
development (as shown by deletion using the Nestin
promoter-driven Cre recombinase).
Whereas Krit1, Ccm2 and Pdcd10 have similar wide-
spread expression patterns in the mouse [32,39–42], the
expression of the mouse orthologue of heart of glass
(Heg1) is restricted to the endothelium and endocar-
dium. Unlike zebraﬁsh, Heg1 knockout mice do not
phenocopy Krit1 or Ccm2 knockouts [26]. Rather,
Heg1 knockout mice die later in gestation or in early
postnatal stages with a variety of cardiac, vascular and
lymphatic defects. Although pulmonary hemorrhage,
cardiac rupture or chylous effusions may variably be
the mechanism of death, a common theme throughout
was disruption of the cell–cell junctions within the
endothelial or endocardial cells. Heg1 and Ccm2 were
also shown to genetically interact in the mouse as pre-
viously seen in ﬁsh [26]. Mice with both homozygous
knockout of Heg1 and heterozygous for Ccm2 were
found to have a much more severe phenotype than
either mutant in isolation. These dual knockouts phe-
nocopy mice with homozygous knockout of Ccm2 or
Krit1.
Multiple lines of investigation implicate a role for
impaired cell-to-cell communication and endothelial
cell junction integrity in states of CCM protein deﬁ-
ciency. Endothelial cell tight junctions are required to
retain cells and macromolecules within the vasculature
and to prevent vascular leak. Although mice heterozy-
gous for Ccm2 do not frequently develop CCM lesions
like their human counterparts, these mice were shown
to have abnormal vascular leak in the dermis when
stressed with vascular endothelial growth factor [33].
Tight junctions are signiﬁcantly regulated by the Rho
family of GTPases. Endothelial cell culture experi-
ments had implicated abnormally increased activity
of RhoA in vitro. A role for increased RhoA activity
in vivo was suggested by the ability of statins – known
inhibitors of Rho GTPases [43] – to rescue the
A B
Fig. 3. Narrowed arteries associated with
circulation failure in mice lacking Ccm2. The
connections of the heart to the aorta, and
the associated cranial portions of the dorsal
aorta are narrowed in mice lacking Ccm2.
The paired dorsal aortae in a wild-type
embryo at E9.0 are shown in (A) (arrows),
stained for the endothelial marker CD31.
Although endothelial cells are present in the
correct location in a Ccm2 gene trap mutant
littermate (arrows in B), little to no lumen is
formed to support circulation.
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7abnormal vascular leak of Ccm2 heterozygous knock-
out mice [33].
It is not clear what is responsible for the difference
in susceptibility between mice and humans for the cere-
bral vascular lesions. Although differences in lifespan
and brain mass may contribute to the lack of vascular
lesions in Krit1 or Ccm2 heterozygous knockout mice,
modifying factors are being sought which increase the
risk of CCM lesion formation. As discussed above,
observational studies in CCM patients suggest that a
‘two-hit hypothesis’ may underlie some lesions. Taking
advantage of the high rate of spontaneous mutations
in mice lacking the tumor suppressor p53, Krit1 het-
erozygous knockouts have been mated onto a p53
knockout background [44]. It was hoped that this
model would reproduce both the human genotype
(two genetic hits) and phenotype (cavernous malforma-
tions). Cerebral vascular lesions were observed in a
high proportion of animals on this background with
characteristics varying from capillary telangiectasias to
more complex cavernous malformations, but the
potential second hit mutation was not found. Unfortu-
nately, mice lacking p53 have a shortened lifespan
because of a high frequency of spontaneous tumors,
including occasional brain tumors [13,45], It is unfeasi-
ble to study the natural history of CCM disease in
these mice as they die from tumor burden shortly after
developing CCM lesions. Great caution must be taken
when interpreting the genetic contribution to vascular
lesions on this background with potential for cancer-
related vascular dysregulation and other physiologic
stressors that may contribute to CCM lesion develop-
ment. These results suggest, however, that a two-hit
model may produce malformations useful for study;
this second hit could come from recombination medi-
ated by an inducible promoter driving Cre recombin-
ase, thereby eliminating the confounding effects of the
p53 null background.
Discussion
Vascular malformations result in considerable morbid-
ity and mortality, especially with respect to lesions of
the central nervous system. The ability to prevent or
treat such lesions requires a greater understanding of
the underlying biology of lesion formation. In this
regard, cerebral cavernous malformation as a genetic
disorder offers unique opportunities to understand
the biology of vascular malformations. Initial insights
regarding the biochemistry of the CCM genes left a
considerable gap in understanding between protein
function and lesion biology. By exploring the function
of the CCM genes in animal models this gap is being
bridged. Animal models have demonstrated the cen-
tral importance of endothelial cell–cell interactions in
the pathogenesis of CCM vascular disease. Endothe-
lial cells need to be coordinated to organize into
proper sized lumens and to maintain vascular barrier
function. As a result of research into CCM, it
becomes apparent that vascular malformations
may result from the loss of genes crucial to vascular
stability.
In addition to providing the important in vivo con-
text for insights gained from biochemistry, animal
models can allow an acceleration of translational
research to ultimately impact the patients and families
with CCM. Recent work in mice shows the promise of
this approach, in that testable phenotypes can be iden-
tiﬁed and potential therapies can be evaluated in mice
genetically similar to CCM patients. Manipulations of
the current animal models to more closely mimic
human disease also appear promising. Ultimately, we
hope that a complete model of CCM lesion biology
can be developed to act as a vital link between bench
and bedside.
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CHAPTER 2
THE CEREBRAL CAVERNOUS MALFORMATION
SIGNALING PATHWAY PROMOTES VASCULAR
INTEGRITY VIA RHO GTPASES
The following chapter was reprinted with permission from Nature Publishing
Group.  In addition to myself, the other authors were Kevin Whitehead, Sutip
Navankasattusas, Wonshill Koh, Nyall London, Jing Ling, Anne Mayo, Stavros Drakos,
Christopher Jones, Weiquan Zhu, Douglas Marchuk, George Davis, and Dean Li.  It was
originally published in Nature Medicine, 2009 Feb;15(2):177-84. Epub 2009 Jan 18.  I
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biochemistry, and the adult in vivo phenotype.
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The cerebral cavernous malformation signaling pathway
promotes vascular integrity via Rho GTPases
Kevin J Whitehead1,2, Aubrey C Chan2, Sutip Navankasattusas2, Wonshill Koh3, Nyall R London2, Jing Ling2,
Anne H Mayo3, Stavros G Drakos2, Christopher A Jones2, Weiquan Zhu2, Douglas A Marchuk4,
George E Davis3 & Dean Y Li1,2
Cerebral cavernous malformation (CCM) is a common vascular dysplasia that affects both systemic and central nervous system
blood vessels. Loss of function mutations in the CCM2 gene cause CCM. Here we show that targeted disruption of Ccm2 in mice
results in failed lumen formation and early embryonic death through an endothelial cell autonomous mechanism. We show that
CCM2 regulates endothelial cytoskeletal architecture, cell-to-cell interactions and lumen formation. Heterozygosity at Ccm2, a
genotype equivalent to that in human CCM, results in impaired endothelial barrier function. On the basis of our biochemical
studies indicating that loss of CCM2 results in activation of RHOA GTPase, we rescued the cellular phenotype and barrier function
in heterozygous mice with simvastatin, a drug known to inhibit Rho GTPases. These data offer the prospect for pharmacological
treatment of a human vascular dysplasia with a widely available and safe drug.
Cerebral cavernous malformations are common vascular malforma-
tions that affect the systemic and central nervous system (CNS)
vasculature with a prevalence of 1 in 200 to 250 individuals1,2 in
unselected populations. CCM consists of enlarged microvascular
channels lined by a single layer of endothelium without smooth muscle
support. Individuals with these vascular lesions are subject to an
unpredictable risk of hemorrhage for which no pharmacologic therapy
currently exists3. Even before overt hemorrhage all lesions are sur-
rounded by hemosiderin—iron-laden deposits that result from extra-
vascular blood and that can be sensitively detected by magnetic
resonance imaging4—suggesting abnormalities in endothelial barrier
function5. Although lesions have been described in a variety of vascular
beds6, clinical manifestations are most common in the CNS, where the
consequences of leak and hemorrhage can be stroke, seizure or death. A
large proportion of cases are familial with an autosomal dominant
pattern of inheritance. Genetic studies have shown that heterozygous
loss of function mutations in CCM2—also known as osmosensing
scaffold for mitogen-activated protein kinase kinase kinase-3 (OSM),
and encoding a protein also known as malcavernin or MGC4607—
cause cavernous malformations7,8. Two other structurally unrelated
genes, KREV1 interaction trapped-1 (KRIT1)—also known as CCM1
(refs. 9,10)—and programmed cell death 10 (PDCD10)—also known
as CCM3 (ref. 11)—have also been associated with CCM. Before the
human genetic studies, there was little to recommend these genes as
obvious candidate genes for any vascular disease.
CCM2 was identified in a screen for genes involved in the cellular
response to osmotic shock12. These stress-activated pathways include
signaling cascades involving Rho-family GTPases such as RHOA,
RAC1 and CDC42, and mitogen-activated protein kinases (MAPKs)
such as p38 and JNK. In fibroblasts, CCM2 is required for the
assembly of a complex between the mitogen-activated protein kinase
kinase kinase-3 and its substrate, mitogen-activated protein kinase
kinase-3 (MKK3), to phosphorylate p38 in response to signaling from
the GTPase RAC1 (ref. 12).
Efforts to incorporate these biochemical insights into a molecular
model to explain the pathogenesis of CCM have been plagued by
controversy over the identity of the cell type in which CCM2 is
required. Although a compromised vasculature defines CCM, there
are compelling data to suggest a neuronal role in the etiology of the
disease. First, the three genes involved in CCM are expressed neither
specifically nor strongly in the endothelium in culture or in animal
models13–15. Second, a precedent for a nonautonomous effect of a
gene affecting vascular integrity exists: neural deletion of the gene
encoding av integrin disrupts the cerebral vasculature and causes
hemorrhage in mice16. Conversely, KRIT1 can act as an effector of the
small GTPase RAP1A in cultured endothelial cells17. The tissue
specificity of Ccm2 function remains unknown. Here we seek to use
genetically manipulated mice to understand the role of Ccm2 in
development, elucidate the mechanism of signaling and explore
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Ccm2 is required for angiogenesis
A putative null allele of Ccm2 with a gene-trap–induced mutation was
identified14. This allele has been termed Ccm2Gt(RRG051)Byg (hereafter
designated Ccm2tr), and consists of an insertion of the gene-trap
vector into exon 6 of Ccm2 and a 45-nucleotide deletion of the
genomic sequence14, disrupting transcription of Ccm2 (Supplemen-
tary Fig. 1a–c online). Mice heterozygous for Ccm2tr are viable and
fertile as previously reported14. We observed no homozygous mutant
mice at weaning. We identified mutant embryos in mendelian ratios
until embryonic day 9 (E9.0). Starting at E9.0, we noticed a gross
phenotype in homozygous Ccm2tr mice (Supplementary Table 1
online). The homozygous mutant embryos failed to organize the
yolk sac vasculature and showed evidence of growth arrest at E9.0
(data not shown). Pericardial effusions subsequently developed before
embryo resorption at E11.5. No viable homozygous mutants were
observed at E9.5 and beyond. The timing of death in these embryos is
consistent with failed angiogenesis.
We studied embryos at E8.5 before the mutant phenotype could be
grossly detected. Embryos were stained with antibodies against the
endothelial cell surface protein CD31 (PECAM) or a-smooth muscle
actin and examined with whole-mount confocal immunofluorescence
microscopy or sectioned and studied by immunohistochemistry. The
initial patterning of the dorsal aorta (Supplementary Fig. 1d,e) and
yolk sac primary vascular plexus (data not shown) by vasculogenesis18
was intact in mutants. Heart development was also normal (data not
shown). After the initial vascular pattern was established, however,
profound defects occurred in the development of subsequent vessels
by angiogenesis (Fig. 1a,b). The first defects observed in mutant
embryos included abnormalities of the first branchial arch artery
and the intersomitic arteries at E8.5 (Fig. 1a,b and Supplementary
Fig. 1e,f). The first branchial arch artery, required to connect the
dorsal aorta to the heart, failed to form a
proper lumen. Adjacent portions of the aorta
were also narrow and irregular, whereas the
previously normal caudal portion of the dor-
sal aorta become enlarged (Supplementary
Fig. 1d). Yolk sac vascular remodeling was abnormal (data not
shown). The failure of the branchial arch arteries had profound
physiologic consequences on the embryo. In vivo ultrasound studies
showed that, despite normal frequency of cardiac contractions, circu-
lation was not established in homozygous mutants (Fig. 1c and
Supplementary Movies 1 and 2 online). Branchial arch artery failure
was not confined to the arteries of the first arch. The second and third
pair of branchial arch arteries should normally form by E9.5. We
injected India ink into the ventricles of mutant embryos at E9.5 and
did not observe passage of ink into the dorsal aorta of mutants
(Fig. 1d). Unlike the anterograde flow observed in wild-type litter-
mates, ink passed retrogradely from the ventricle through the atrium
and into the common cardinal vein in mutant embryos (Fig. 1d).
Growth arrest and embryonic death resulted from the failed circula-
tion first observed at E8.5.
Ccm2 is required in the endothelium
The phenotype of mice with gene-trap mutations in Ccm2 establishes
an essential role for this protein in angiogenesis. This mutation is
present in all cells of the embryo and thus does not make clear which
tissues require Ccm2 for normal function. To determine the tissue
requirement for Ccm2, we developed mice with a conditional muta-
tion in Ccm2 by Cre-lox technology (Supplementary Fig. 2 online).
This allele is termed Ccm2tm1Kwhi (hereafter referred to as Ccm2fl). The
Ccm2 gene remains intact until the allele is exposed to Cre recombi-
nase, which deletes exons 3–10 of Ccm2. Mating Ccm2fl/+ mice with
HPRT-Cre mice19 expressing Cre recombinase in the germline resulted
in a heritable mutant allele termed Ccm2tm1.1Kwhi hereafter referred to
as Ccm2–). Homozygous Ccm2–/– mutant mice phenocopy the gene-
trap (Ccm2tr/tr) mutants (Supplementary Fig. 2e). Cre recombinase
can also be expressed in a tissue-specific manner under the control of






















































b Figure 1 Ccm2 is required for blood circulation.
(a) Whole-mount confocal immunofluorescence
micrographs of littermate embryos at E8.5
showing abnormal vasculature in Ccm2tr/tr (right).
(b) Higher magnification of the first branchial
arch arteries (BAA1) and dorsal aorta (DA).
Cartoons at the bottom show orientation. Ccm2-
mutant vessels (single arrows) are narrower at
BAA1 and adjacent portions of the dorsal aorta
than wild-type vessels (double arrows). (c) Fetal
ultrasound showing no blood flow in a Ccm2tr/tr
embryo (bottom row) at E8.5 despite a normal
frequency of cardiac contractions (middle panels).
Blood flow (colorized pixels) was observed in wild-
type littermates (top row). Diagrams at left show
orientation. DA, dorsal aorta; YS, yolk sac
(also see Supplementary Movies 1 and 2).
(d) Photographs after ink injection into the
cardiac ventricle. Ink passage through the
branchial arch arteries at E9.5 was observed
in a wild-type embryo (top) but no anterograde
passage through the branchial arches (red arrow)
into the aorta was observed in a Ccm2 tr/tr
littermate (bottom). Scale bars: a,c,d, 500 mm;
b, 200 mm. Results are representative of multiple
(minimum eight) paired observations.
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tissue-restricted, somatic mutants for defects in angiogenesis. Mice
lacking Ccm2 in the endothelium (Ccm2fl/–;Tg(Tie2-Cre))20 resemble
germline mutants with similar vascular defects and timing of embryonic
death (Table 1 and Fig. 2). Endothelial cell–specific deletion of Ccm2 is
uniformly lethal during development (Table 1 and data not shown).
The expression of Ccm2 in neural tissues and the predominance of
CCM lesions in the CNS suggest a possible role for Ccm2 in neural
cells. Mice lacking Ccm2 in neural tissues were generated with Cre
driven by a nestin promoter (Ccm2fl/–;Tg(Nes-Cre))21. These mutant
mice had no defects in angiogenesis at E9.0 and were found in the
expected ratios at birth (Table 1 and Fig. 2). Another key contributor
to the milieu of endothelial cells in vivo is the smooth muscle cell.
Mice lacking Ccm2 in smooth muscle cells were generated with a
transgelin-Cre (Ccm2fl/–;Tg(Tagln-Cre))22. Like the mice lacking Ccm2
in neural tissues, mice lacking Ccm2 in smooth muscle were also
found at birth, with normal vasculature at E9.0 (Table 1 and Fig. 2).
These data indicate an essential role for Ccm2
only in endothelial cells for the initial events
of angiogenesis.
CCM2 regulates lumen formation via the
actin cytoskeleton
Our genetic studies led us to evaluate the
function of CCM2 in human endothelial
cells. We detected CCM2 expression by
real-time quantitative RT-PCR in human
mictrovascular (dermal) endothelial cells
(HMVECs) and human umbilical vein
endothelial cells (HUVECs; Fig. 3a). A single
small interfering RNA (siRNA) construct
specific for CCM2 (CCM2 siRNA) was able to decrease the amount of
CCM2 transcripts by 80–90% in HMVECs and HUVECs (Fig. 3a).
Endothelial cells in three-dimensional culture spontaneously
develop tube-like structures that resemble the microvasculature and
that model events in developmental angiogenesis23. We tested the role
of CCM2 in lumen formation in vitro by comparing HUVECs treated
with CCM2 siRNA with either a luciferase or a random negative
control siRNA in this three-dimensional assay of tube morphogenesis
(Fig. 3b,c and Supplementary Movies 3 and 4 online). Control
HUVECs formed vacuoles that coalesced into tube-like structures
over the course of 24 h, whereas CCM2-depleted HUVECs formed
fewer lumens with a much smaller lumen cross-sectional area
(Fig. 3d,e). This defect was observed at the single-cell stage before
the formation of multicellular structures (Fig. 3d). These observations
suggest a crucial and endothelial intrinsic role for CCM2 in the




























Table 1 Embryonic development in mice with tissue specific deletions of Ccm2
Endothelial Neural and glial Smooth muscle
Ccm2fl/+ Ccm2fl/– Ccm2fl/+ Ccm2fl/– Ccm2fl/+ Ccm2fl/–
Developmental stage Tg(Tie2-Cre) No Cre Tg(Tie2-Cre) No Cre Tg(Nestin-Cre) No Cre Tg(Nestin-Cre) No Cre Tg(Tagln-Cre) No Cre Tg(Tagln-Cre) No Cre
E9.0 4 12 13 9 6 7 7 5 6 4 6 2
E15.5 4 4 0 5 7 10 3 8 5 7 6 7
P0.5 17 18 0 7 4 4 7 2 9 11 3 8






Ccm2 fl/– Ccm2 fl/– Ccm2 fl/–
No Cre









Neural + glial Smooth musclea
b
Figure 2 Vascular defects in mutant mice are
endothelial cell autonomous. (a) Whole-mount
immunofluorescence showing normal, uniform
caliber branchial arch arteries and aortas in all
Ccm2fl/– embryos except the endothelial (Tie2-
Cre) mutant, which has an irregular, narrow
lumen (red arrowheads). Cartoons at the bottom
are provided for orientation. BAA1, first branchial
arch artery; BAA2, second branchial arch artery;
VA, ventral aorta (or aortic sac); DA, dorsal aorta.
(b) Paraffin sections taken at E9.0 showing
narrow branchial arch arteries in mutant embryos.
In contrast to the wild-type embryo (left), the first
branchial arch artery (arrowhead) is similarly
narrowed and irregularly shaped in both complete
knockout (Ccm2tr/tr, middle) and endothelial
mutant (Ccm2fl/–;Tg(Tie2-Cre), right) embryos.
Scale bars, 200 mm. Results are represen-
tative of multiple (minimum seven)
independent observations.
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expansion of these structures to form the vascular lumen. Consistent
with this hypothesis, we observed upregulation of CCM2 messenger
RNA by RT-PCR in a time course parallel with lumen formation in
control HUVECs (Fig. 3f). The failure in lumen formation is not a
consequence of insufficient endothelial migration or of an inability to
form filopodial sprouts: HUVECs treated with CCM2 siRNA showed
increased sprouting of cell processes when initially plated in three-
dimensional culture (Fig. 3g), and HMVECs treated with CCM2
siRNA showed increased haptotactic migration (Fig. 3h).
Lumen formation is dependent upon the cellular cytoskeleton24.
CCM2-deficient HMVECs had a marked increase in formation of
actin stress fibers traversing the cell, with less cortical actin at the cell
periphery (Fig. 4a). Actin redistribution correlated with a decrease in
barrier function and increased permeability of the endothelial mono-
layer (Fig. 4b,c). We observed decreased electrical resistance and
increased transit of macromolecules (horseradish peroxidase (HRP))
across CCM2-deficient monolayers compared to control cell mono-
layers (Fig. 4b,c).
CCM2 regulates actin and MAPK via RHOA
The Rho family of small GTPases regulates many aspects of the
structure and function of the cellular cytoskeleton. Impaired lumen
formation24, increased formation of actin stress fibers and decreased
barrier function25 in endothelial cells suggest activation of RHOA.
Consistent with the cellular phenotype, we observed increased active
(GTP-bound) RHOA in CCM2-depleted HMVECs compared to con-
trol cells (Fig. 4d). We found no change in the activation of RAC1 and
found less basal activation of CDC42 (Fig. 4d). By immunoprecipita-
tion, we found that CCM2 binds RHOA and RAC1 but not CDC42
(Fig. 4e). Inhibition of RHOA signaling either at the level of RHOA
with C3 transferase26 or downstream at the level of Rho kinase (ROCK),
with the ROCK inhibitor Y-27632 (ref. 27) blocked the stress fiber
response of CCM2-depleted HMVECs (Fig. 4f). C3 transferase was also
able to significantly rescue barrier function in these cells (Fig. 4g).
CCM2 has also been implicated in MAPK signaling12. We used
phospho-specific antibodies to profile the activation state of MAPK
family members in the absence of CCM2 (Fig. 4h). The main families
of MAP kinases are the extracellular signal regulated kinases (ERKs),
p38 and JNK, with p38 and JNK also known as stress-regulated
protein kinases28. A reduction in CCM2 transcript levels did not
affect the amount of either phosphorylated ERK or phosphorylated
p38 but did increase phosphorylation of JNK and its upstream kinases
MKK4 and MKK7. As GTPases can stimulate MAPK signaling, we
tested whether increased JNK activation was the result of increased
Rho activity by treating cells with the ROCK inhibitor Y-27632. ROCK
inhibition decreased the activation of JNK (Fig. 4i). These observa-
tions suggest that the loss of CCM2 leads to RHOA activation, causing
activation of JNK with an associated change in endothelial phenotype
including cytoskeletal changes, impaired lumen formation and
increased migration and vascular permeability.
Simvastatin rescues CCM2 deficiency in vivo
Humans with CCM have heterozygous mutations in CCM2 and suffer
from vascular hemorrhage or leakage, but not from severe develop-
mental angiogenic defects as observed in mice with homozygous
mutations in Ccm2. To examine the role of Ccm2 in the disease state,
we shifted our attention to mice heterozygous for Ccm2. We found no
difference in vascular patterning (data not shown) or permeability to
the intravascular dye Evans blue between heterozygous mice and wild-
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Figure 3 CCM2 is required for endothelial tube morphogenesis. (a) Quantitative RT-PCR for
CCM2 transcript in HMVECs and HUVECs after treatment with control (random) siRNA or CCM2
siRNA. A minimum of three independent experiments were performed. (b) Toluidine blue staining
of capillary lumen formation in three-dimensional collagen matrices of HUVECs treated with
CCM2 siRNA. Two separate control siRNAs (luciferase siRNA and a random control siRNA) were
used for comparison. (c) Time-lapse photography of tube development in endothelial cells treated
with CCM2 siRNA compared with luciferase siRNAs. Arrows denote organization of lumenized
structures from vacuole precursors. (d) Quantification of lumen and vacuole development over time in HUVECs treated with CCM2 siRNA as compared to a
luciferase (Luc) siRNA control. Five fields were analyzed for each data point. (e) Quantification of lumen numbers at 24 h in HUVECs treated with CCM2
siRNA compared to luciferase or random siRNA controls. EC, endothelial cell; hpf, high power field. Three fields were analyzed for each siRNA. (f) CCM2
levels assayed by RT-PCR in control HUVECs undergoing tube formation at various stages of the vacuole and lumen formation assay. (g) Quantification of
filopodial length in HUVECs treated with CCM2 siRNA compared to a luciferase siRNA control. Ten fields were analyzed for each siRNA. (h) Haptotactic
migration of HMVECs to fibronectin in CCM2-depleted cells versus random siRNA control–treated cells. Analysis was performed on twelve control and eight
CCM2 siRNA fields. Scale bars, 100 mm. Values are means ± s.e.m., except in e, where values are means ± s.d.
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or genetic32 stressors may have a role in disease pathogenesis. An
association was observed between accelerated progression of CCM and
increasing amounts of vascular endothelial growth factor (VEGF)29.
Consistent with this clinical observation, we observed significantly
increased permeability to Evans blue in Ccm2+/tr mice in response to
VEGF across a range of doses (Fig. 5a). Increased permeability was also
observed in mice with endothelial-specific heterozygosity for Ccm2
(Fig. 5b). These results demonstrate a role for Ccm2 in the endothe-
lium for the maintenance of normal in vivo barrier function in adults
aside from its role in embryonic development.
Our observations in vitro suggested that Rho inhibition might
rescue the increased permeability of Ccm2-heterozygous mice. How-
ever, mice do not tolerate the ROCK inhibitor Y-27632 (data
not shown), and the Rho inhibitor C3 transferase has poor
cellular penetration, limiting its usefulness in vivo. Inhibitors of
3-hydroxy-3-methyl-glutaryl-CoA reductase (statins) have pleiotropic
effects that include the inhibition of Rho GTPases. Simvastatin
disrupts the production of key intermediaries in the cholesterol
synthesis pathway necessary for RHOA isoprenylation33,34 and has
been used as an inhibitor of Rho in vivo35,36. In culture, we found that
simvastatin reduced formation of actin stress fibers in both control
and CCM2 siRNA–treated endothelial cells (Fig. 5c) and decreased
haptotactic migration of CCM2-depleted HMVECs (Fig. 5d). Simva-
statin also decreased the phosphorylation of JNK in both control and
CCM2 siRNA–treated cells (Fig. 5e). In vivo, we found that pretreat-



































































































































































































Figure 4 CCM2 deficiency alters the endothelial cytoskeletal architecture and cell-cell interactions via activation of the small GTPase RHOA. (a) Confocal
immunofluorescent visualization of cellular cytoskeleton (actin fibers) and cell junctions (b-catenin) in HMVECs treated with CCM2 or random control siRNA.
Results are representative of three independent experiments. (b) Endothelial monolayer permeability to HRP in HMVECs treated with CCM2 or random
control siRNA, as determined by absorbance at 490 nm (A490). (c) Transendothelial resistance in CCM2-depleted HMVECs compared to control–treated cells.
(d) GTPase pulldown assays for GTP-bound (active) RHOA, RAC1 and CDC42 in control and CCM2-depleted cells. Results are representative of three
independent experiments. (e) Immunoprecipitation assays for CCM2 binding to Rho family GTPases. Myc, construct with myc epitope tag; Vec, empty vector
control; V5, construct with V5 epitope tag; IP, immunoprecipitation; Anti, antibody to the indicated protein. Results are representative of three independent
experiments. (f) Fluorescent phalloidin staining for actin stress fibers in HMVECs after treatment with inhibitors of Rho signaling. Results are representative
of three independent experiments. (g) Time course of transendothelial electrical resistance in CCM2-depleted HMVECs compared to cells treated with
either C3-transferase or control. (h) Immunoblot analyses of phosphorylated (active) MAP kinases and the JNK upstream kinases MKK4 and MKK7. p-Ab,
phosphorylated kinase; t-Ab, total kinase. Results are representative of three independent experiments. (i) Immunoblot analysis of cell lysates for
phosphorylated and total JNK after treatment with the Rho–kinase inhibitor Y-27632. Results are representative of three independent experiments.
Scale bars, 50 mm. Values are means ± s.e.m. For b, c and g, a minimum of three independent experiments were performed.
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response of Ccm2+/tr mice to VEGF with no effect on the induced
permeability of Ccm2+/+ mice (Fig. 5f). These data suggest that the
abnormal Rho GTPase activity observed in cells depleted of CCM2 is
also present in mice with reduced levels of Ccm2.
DISCUSSION
We show here that mice lacking Ccm2 die in mid-gestation from failed
angiogenesis and that these vascular defects are endothelial autono-
mous, providing what is to our knowledge the first in vivo evidence
that any of the genes causing CCM are required in the endothelium.
Using two distinct mutations in the Ccm2 gene, we show that Ccm2 is
not required for the initial differentiation of endothelial cells from
angioblast precursors (vasculogenesis)18, but, rather, is required for
subsequent vessel formation and remodeling (angiogenesis) In mice
lacking Ccm2, the branchial arch arteries, the first essential angiogenic
vessels, fail to form a stable lumen. As a result, the heart is not
functionally connected with the vasculature, and circulation fails to
initiate. Subsequent growth and development of the embryo is severely
impaired, and death ensues. Tissue-specific mutants show that selec-
tive deletion of Ccm2 in the endothelium is sufficient to reproduce the
vascular defects, whereas mice lacking Ccm2 in neural or smooth
muscle cells develop normally. Thus, Ccm2 is required in the
endothelium for angiogenesis.
The recognition of an autonomous function for Ccm2 in endothe-
lial cells allowed us to examine previous biochemical studies in a new
light. Such studies in fibroblasts and other nonendothelial cell types
suggested a role for CCM2 as a scaffold tying RAC1 GTPase activity to
p38 activation in response to osmotic stress12. Endothelial cells face
stressors in the context of a monolayer of interacting cells. In addition
to the maintenance of individual cell size and shape in the face of
stress, endothelial cells must also maintain contact and barrier func-
tion with adjacent cells in the monolayer. One might expect that
CCM2, as a key molecule in response to stress, would have a role in
maintaining stable endothelial cytoskeletal architecture and cell-to-cell
interactions. Our observations in CCM2-depleted HMVECs support
this hypothesis: these cells showed a loss of cortical actin, increased
formation of actin stress fibers and decreased endothelial barrier
function, changes that are typically caused by activated RHOA
GTPase25 and that can be reversed by inhibitors of RHOA signaling.
Our observations suggest a model whereby a dynamic equilibrium
between vascular stability and instability exists. The endothelium of a
stable blood vessel provides crucial barrier functions by controlling
fluid, nutrient and cellular transport between intravascular and extra-
vascular compartments. The formation and maintenance of strong
cell-to-cell contacts is a favorable characteristic of endothelial cells in a
stable blood vessel. However, when challenged by injury or inflamma-
tion, the endothelium alters its phenotype and temporarily disrupts
cell-to-cell junctions. In this destabilized state, the endothelium can
initiate the required migration and angiogenesis responses to the
stressor. In this model, CCM2 is required for endothelial cells to assume
the stable phenotype, mediated at least in part by limiting RHOA
activation24,37,38. Our cell culture data indicate that CCM2 regulates key
aspects of the stabilized endothelium, including cellular architecture,
barrier function, migration and tube morphogenesis. Loss of CCM2
favors the destabilized phenotype. In wild-type mice, with two func-
tioning alleles of CCM2, the intensity and duration of instability after
insult is limited. In heterozygous mice with only one functioning allele,
there is a greater disruption of the stable state with increased perme-
ability in response to VEGF. With the loss of both alleles of Ccm2 in the
endothelium, stability cannot be achieved—existing vessels enlarge and
excessive but dysfunctional angiogenic sprouts form, which are unable
to develop stable lumens to allow functional circulation.
This model might also explain the development of cavernous
angiomas in familial CCM. Previously, a ‘two-hit’ hypothesis involving
biallelic somatic and germline mutations was proposed to explain the
focal nature of vascular lesions in human CCM, supported by a single
case report32. The focal loss of the only remaining allele of CCM2
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Figure 5 Heterozygous Ccm2+/tr mice have permeability defects
that can be rescued by treatment with simvastatin. (a) Spectro-
photometric quantification of Evans blue extravasation in the Miles
assay of dermal permeability in Ccm2 +/tr versus Ccm2 +/+ mice
across a range of doses of VEGF compared to saline control. Five
mice were studied for each genotype. (b) Quantification of dermal
permeability in mice with endothelial specific heterozygosity for
Ccm2 (Ccm2 fl/+;Tg(Tie2-Cre)) compared to mice with both Ccm2
alleles intact (Ccm2 fl/+) and mice with complete Ccm2
heterozygosity (Ccm2 fl/–). We studied five Ccm2 fl/+ mice, nine
Ccm2 fl/ mice and ten Ccm2fl/+;Tg(Tie2-Cre) mice. (c) Phalloidin
staining for cellular actin fibers after treatment with carrier or simvastatin. Results are representative of three independent experiments. (d) Haptotactic
migration of HMVECs to fibronectin after treatment with CCM2 or random control siRNA and treatment with either simvastatin or ethanol carrier. A minimum
of three independent experiments were performed. (e) Immunoblot for phosphorylated and total JNK in HMVECs treated with CCM2 or random control siRNA
and treated with either simvastatin or ethanol carrier. Results are representative of three independent experiments. (f) Quantification of Evans blue
extravasation in the Miles assay in response to saline or VEGF after pretreatment with simvastatin or ethanol carrier. For both genotypes, we used three mice
with control treatment and four mice with simvastatin treatment. Scale bars, 100 mm. Values are means ± s.e.m.
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in a cavernous angioma. Our in vivo experiments suggest the possi-
bility that the second hit may not be limited to genetic disruptions but
could also take the form of recurrent exposure to cytokines such as
VEGF that are released locally in response to stress or inflammation.
The unique importance of strong endothelial cell-to-cell interaction in
the central nervous system might render this vascular bed particularly
sensitive to such perturbations. The importance of a physiologic
response to stress as a second hit could explain the clinical association
between elevated levels of VEGF and the rapid progression of CCM29.
Thus, in retrospect, a gene originally identified for its role in the
cytoskeletal response to stress should have been an obvious candidate
gene for human vascular dysplasias. The efficacy of statins in rescuing
Ccm2-related vascular pathology in mutant mice suggests a pharma-
cological strategy for treating patients whose therapeutic options are
currently limited to brain surgery or radiation.
METHODS
Fetal ultrasound. We studied pregnant mice under isoflurane anesthesia on a
heated stage, with continuous monitoring of electrocardiogram and respira-
tion. After laparotomy, we studied embryos within 45 min. We determined
genotype correlation with ultrasound findings by recording the position of the
embryos in the uterus relative to the position in the abdomen by ultrasound.
We used a Vevo 660 ultrasound machine (VisualSonics) with a 40-MHz
transducer for imaging. We used digital subtraction to illustrate circulating
blood in static images (Supplementary Methods online). We determined heart
rates by M-mode ultrasound.
Ink injection. We injected India ink as previously described39.
Endothelial cell vasculogenesis in three-dimensional collagen matrices. We
suspended HUVECs (passages 2–5) within 3.75 mg ml–1 of collagen type I
matrices and allowed them to undergo morphogenesis as described40. We fixed
cultures with 3% glutaraldehyde for 30 min. We stained some cultures with
0.1% toluidine blue in 30% methanol and destained before photography and
visualization. We performed time-lapse microscopy as previously described41
with a Nikon TE2000U microscope with attached environmental chamber. We
examined time-lapse images for total area of both vacuoles and lumens (n ¼ 5
independent fields) and total process length from all cells (n ¼ 10 fields). We
quantified the number of lumens per field at 24 h (n ¼ 3 fields). We used
Metamorph (Molecular Devices) software to trace and quantify lumen area and
process length.
Endothelial cell haptotaxis. We examined haptotactic migration with a
modified Boyden chamber assay (Neuro Probe). We coated polycarbonate
membranes (8-mm pores) with human fibronectin (1 mg ml–1, Biomedical
Technologies) on the lower surface. We added HMVECs to the upper well
(20,000 cells per well) in endothelial growth medium-2 and allowed them to
migrate for 3 h. We fixed and stained the membranes (Hema3 kit, Fisher),
removed nonmigrated cells and mounted the membrane on a glass slide. We
counted the number of migrated cells per high-power field for multiple fields
and replicates (control, n ¼ 12 fields; CCM2, n ¼ 8 fields). For simvastatin
rescue experiments, we treated cells with either 10 mM simvastatin (Calbio-
chem) or ethanol carrier for 24 h before the assay (n ¼ 3 fields per condition).
Horseradish peroxidase permeability. We coated transwell inserts (Corning,
48-well, 3-mm pore) with human fibronectin and seeded them with 30,000 cells
per well. We added HRP (25 mg ml–1, Sigma) to the top of the insert. We
asssayed solution from the bottom of the well for HRP 6 h later by colorimetric
assay. We mixed the sample with guaicol (Sigma) and hydrogen peroxide
(Fisher) and measured for absorbance at 490 nm (n ¼ 6 wells each).
Transendothelial resistance. We coated an electrode culture array (Applied
Biophysics) with human fibronectin and seeded it at 50,000 cells per well. Three
days after seeding, we serum-starved cells in endothelial basal medium-2 with
0.2% BSA overnight. We measured transendothelial resistance with an electric
cell-substrate impedance sensing system (Applied Biophysics). We added cell-
permeable C3 transferase (1 mg ml–1) to inhibit RHOA. For basal resistance, we
measured 40 wells each; for Rho inhibition experiments, we measured six
control wells each and ten C3 transferase wells each.
Miles assay. We performed tail vein injections of Evans blue (0.5% in normal
saline, Sigma) in 8–12-week-old mice. Thirty minutes later, we injected either
saline or VEGF-165 (R&D Systems, 10 ng) in multiple dermal sites. After an
additional 30 min, we killed the mice, performed punch biopsies and eluted
Evans blue from the biopsies in formamide (Invitrogen) overnight at 60 1C. We
measured the absorbance of Evans blue at 620 nm, subtracting the background
absorbance at 740 nm. We gave simvastatin (20 mg kg–1) as an intraperitoneal
injection 26 h before and 2 h before the intradermal stimuli. For the VEGF
dose-response experiment, we used five mice per group. For the permeability
experiment with conditional Ccm2, we used five Ccm2fl/+ mice, nine Ccm2fl/–
mice and ten Ccm2fl/+;Tg(Tie2-Cre) mice. For the simvastatin experiment,
we used three mice with control treatment and four mice with simva-
statin treatment.
Additional methodology. Mouse strains, histology, confocal immunofluores-
cence of embryos, cell culture, transfection of endothelial cells with siRNAs,
RT-PCR, immunofluorescent cell staining, GTPase activation assays, immuno-
precipitation and MAPK profiling are described in the Supplementary
Methods online.
Mouse experiments. All mouse experiments were approved by the University
of Utah Institutional Animal Care and Use Committee.
Statistical analyses. For in vitro lumen formation and cell process formation in
three-dimensional culture, we performed statistical comparisons between
treatment groups with a two-tailed paired samples t-test with an a value of
0.05. For transwell in vitro permeability, transendothelial resistance, endothelial
cell migration and the Miles assay of dermal permeability, we made group
comparisons by two-tailed Student’s t-test with an a value of 0.05.
Note: Supplementary information is available on the Nature Medicine website.
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Supplementary table 1. Ccm2
tr/tr
 mutant phenotype: 










<E8.5 72 161 79 
E8.5 217 362 177 
E9.0 48 80 2 




Mouse strains.  
Mice with gene trap mutations of Ccm2 were derived from an embryonic stem 
cell clone (Bay Genomics).  A construct for the conditional allele of Ccm2 was 
derived from genomic sequence obtained from a BAC clone (RP22 library, 
Invitrogen).  The construct extended from a SalI site 5’ of exon 3 through a 
BamHI site 3’ of exon 10.  The construct contained inserts as outlined in Fig. S2.  
All mice were backcrossed into the C57BL6/J strain.  Experiments performed 
prior to the 5th cross were performed with littermate controls. LacZ reporter mice 
(R26R1) and Tie2-Cre mice were generously provided by Phil Soriano and 
Masashi Yanagisawa respectively.  HPRT-Cre, Nestin-Cre and Tagln-Cre mice 
were obtained from The Jackson Laboratory. Genotypes were determined by 
PCR analysis of genomic DNA isolated from either ear biopsies or yolk sac 
tissues using primers outlined in Supplementary Fig. 1 and 2 (sequences 
available upon request). 
 
Confocal immunofluorescence of embryos.  
Embryos were prepared for confocal immunofluorescent detection of PECAM 
antigen as previously described1 with the following exception.  For improved 
signal detection in thick specimens, following the final wash steps after applying 
secondary antibody, embryos were processed through graded methanols before 
mounting in benzyl alcohol – benzyl benzoate (BABB) based mounting medium. 
Images were aquired with an Olympus FV300 confocal microscope, and stacks 
were chosen to visualize only one of the paired dorsal aortae. Multiple images 
were required to visualize the entire embryo. Photoshop was used to assemble 
source images into a final composite (image junctions shown in final assembly). 
 
Digital Subtraction.  
Ultrasound images were selected for digital subtraction by choosing frames 
unaffected by motion from maternal respiration. Sequential images were applied 
to each other in Photoshop (Adobe Systems, Inc.) using a subtractive filter to 
remove static portions of the image. Several resulting images of dynamic pixels 
were merged together using an additive filter.  This composite of dynamic pixels 
was colorized using a gradient overlay.  To provide some anatomic perspective, 




Embryos were studied with antibodies to PECAM (1:250 dilution, clone MEC13.3, 
BD Biosciences).  Improved visualization on paraffin sections was obtained using 
a biotinylated tyramide signal amplification (TSA) kit (PerkinElmer) according to 
the manufacturer’s instructions.  Cardiac smooth muscle was demonstrated with 
antibodies to alpha smooth muscle actin (1:500 dilution, clone 1A4, Sigma) 
without signal amplification.  To demonstrate tissue specificity of transgenic Cre 
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lines, embryos with appropriate LacZ reporter alleles were stained with X-gal as 
previously described2. 
 
Cell culture.  
Human umbilical vein endothelial cells (HUVEC) and human dermal 
microvascular endothelial cells (HMVEC) were obtained from Lonza and grown 
according to the manufacturer’s instructions in EGM-2 media (HUVEC) or EGM-
2MV media (HMVEC). Human embryonic kidney (HEK 293T) cells (from ATCC) 
were grown in Dulbecco’s Modified Eagle Medium (DMEM, Gibco) with 10% fetal 
bovine serum (Hyclone) supplemented with antibiotics. 
 
Transfection of ECs with siRNAs.  
Human CCM2 siRNA was obtained from Dharmacon.  Luciferase GL2 duplex or 
scramble siRNA (Dharmacon) were used as a control.  EC transfection with 
siRNAs was carried out in growth media with 1% serum.  Details of the siRNA 
transfection protocol have been described previously3.  
 
Reverse transcription-polymerase chain reaction (RT-PCR).  
Total RNA was extracted from EC vasculogenesis assay at indicated time points 
or from siRNA-treated (Luciferase or CCM2) ECs using the Totally RNA Isolation 
kit (Ambion) according to the manufacturer’s instructions.  RNA (1 µg) was 
reverse transcribed using AccuScript High Fidelity 1st strand cDNA synthesis kit 
(Stratagene).  RT-PCR amplification primer sequences are available upon 
request. For quantitative real-time PCR, total RNA was extracted from cultured 
endothelial cells or from embryos using the NucleoSpin RNA II kit (Clontech) 
according to the manufacturer’s instructions.  Reverse transcription was 
performed with random primers using the RetroScript kit (Ambion).  Quantitative 
PCR was performed with TaqMan assays (Applied Biosystems) for human CCM2 
and GAPDH, or mouse Ccm2 and Gapdh.  Quantification was performed by 
standard curve method, and CCM2 transcripts were normalized to GAPDH for 
comparisons. 
 
Immunofluorescent Cell Staining.  
Glass chamber slides were coated with human fibronectin (Biomedical 
Technologies, Inc.), and transfected cells were seeded at 50,000 cells per well.  
For the RHOA and ROCK experiment, cells were treated 4 d after seeding with 
40 µg mL-1 of cell-permeable C3 transferase (Cytoskeleton, Inc.) or 20 µM Y-
27632 (Santa Cruz Biotechnology) for 4 h.  For the simvastatin experiment, cells 
were treated 3 d after seeding with 40 µM simvastatin or equivalent amounts of 
ethanol in growth media for 24 h.  Cells were fixed in 4% formaldehyde and 
incubated with an antibody against β-catenin (BD Biosciences).  Fluorescent 
secondary antibody (Molecular Probes) was used to visualize β-catenin staining.  
Actin cytoskeleton was visualized using fluorescently-conjugated phalloidin 




GTPase Activation Assays.  
Activity of RHOA, RAC1, and CDC42 were measured using activation assay kits 
(Upstate) according to manufacturer’s instructions.  Briefly, transfected cells were 
scraped into Mg2+ lysis buffer supplemented with protease inhibitors (Roche) and 
phosphatase inhibitors (Sigma).  A small portion of the lysate was retained as 
total cell lysate and the rest was incubated with the assay reagent. GTP-bound 
forms were eluted from the assay reagent using Laemmli sample buffer and 
analyzed by western blotting.  The total cell lysate was analyzed by western 
blotting for total GTPase input.  
 
Immunoprecipitation.  
An EST for CCM2 (IMAGE: 2924210) was obtained from ATCC and cloned into a 
pcDNA3.1 Hygro+ plasmid modified to encode a C-terminal V5 tag.  Constructs 
for myc-tagged RHOA, RAC1, and CDC42 were obtained from Addgene4 
(Addgene plasmid 15899, Addgene plasmid 15902, and Addgene plasmid 15905 
respectively).  Plasmids were transfected into HEK 293T cells using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instructions.  3 d 
post transfection, cells were scraped into lysis buffer (50 mM Tris-HCl at pH 7.5, 
100 mM NaCl, 0.5% Triton X-100) supplemented with protease and phosphatase 
inhibitors.  A portion of cell lysate was retained as whole cell lysate, and the rest 
incubated with antibodies against RHOA (Santa Cruz Biotechnology), RAC1, or 
CDC42 (Upstate) as indicated at 4°C for 2 h, followed by incubation with Protein 
A/G beads (Santa Cruz Biotechnology).  The beads were washed three times 
with lysis buffer and bound proteins were eluted using Laemmli sample buffer.  
Presence of CCM2-V5 was detected using an anti-V5 antibody (Invitrogen).  
Presence of myc-tagged RHOA, RAC1, and CDC42 were detected using an anti-
myc antibody (Santa Cruz Biotechnology). 
 
MAPK Profiling.  
siRNA transfected cells were lysed in RIPA buffer (50 mM Tris pH 7.4, 150 mM 
NaCl, 1% NP-40) supplemented with protease and phosphatase inhibitors.  
Lysates were then analyzed by western blotting.  Antibodies to phospho-JNK and 
total JNK were from Santa Cruz Biotechnology.  Antibodies to phospho-ERK, 
phospho-p38, phospho-MKK4, phospho-MKK7, total ERK, total p38, total MKK4, 
and total MKK7 were from Cell Signaling Technology.  The effect of ROCK 
inhibitor on JNK was tested by treating cells with 10 µM Y-27632 for 30 min prior 
to cell lysis. The effect of simvastatin on JNK was determined by treating cells 
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Nat. Med. 12, 793–800 (2006); published online 25 June 2006; corrected after print 6 April 2009
In the version of this article initially published, the name of one of the authors, Nihar R. Nayak, was misspelled as Nihar R. Niyak. The error has 
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Nat. Med. 15, 42–49 (2009); published online 21 November 2008; corrected after print 6 April 2009
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(y axis) and GR1 expression (x axis). In panel (c), the curves should start at 1 h. In panel (d), the text labeling the y axis should read “in vitro,” not 
“in vivo.” The errors have been corrected in the HTML and PDF versions of this article.
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Nat. Med. 15, 293–299 (2009); published online 15 February 2009; corrected after print 6 April 2009
In the version of this article initially published, a “left” and “right” designation was switched in the legend for Figure 4d. The legend should read 
“FCICA of peripheral blood CD8+ T cells from the four protected vaccinees, examining the response of these cells to SIV proteins that were (Rev-
Tat-Nef) or were not (Pol and Vif) expressed by the administered RhCMV vectors before (left) and 133 d after (right) initiation of the SIVmac239 
intrarectal challenge protocol.” The error has been corrected in the HTML and PDF versions of the article.
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Prashant Nair
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MUTATIONS IN 2 DISTINCT GENETIC PATHWAYS
RESULT IN CEREBRAL CAVERNOUS
MALFORMATIONS IN MICE
The following chapter was reprinted with permission from the American Society
for Clinical Investigation.  In addition to myself, the other authors were Stavros Drakos,
Oscar Ruiz, Alexandra Smith, Christopher Gibson, Jing Ling, Samuel Passi, Amber
Stratman, Anastasia Sacharidou, M. Patricia Revelo, Allie Grossmann, Nikolaos Diakos,
George Davis, Mark Metzstein, Kevin Whitehead, and Dean Li.  It was originally
published in the Jouranl of Clinical Investigation, 2011 May 2;121(5):1871-81. doi:
10.1172/JCI44393, Epub 2011 Apr 1.  I participated in the design, execution,
interpretation of data, and preparation of the manuscript.
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Mutations in 2 distinct genetic pathways result 
in cerebral cavernous malformations in mice
Aubrey C. Chan,1,2 Stavros G. Drakos,1,3 Oscar E. Ruiz,4 Alexandra C.H. Smith,1,4  
Christopher C. Gibson,1,5 Jing Ling,1 Samuel F. Passi,1 Amber N. Stratman,6 Anastasia Sacharidou,6 
M. Patricia Revelo,7 Allie H. Grossmann,1,7 Nikolaos A. Diakos,1 George E. Davis,6  
Mark M. Metzstein,4 Kevin J. Whitehead,1,3 and Dean Y. Li1,2,3,4
1Molecular Medicine Program, 2Department of Oncological Sciences, 3Division of Cardiology, Department of Medicine, 4Department of Human Genetics,  
and 5Department of Bioengineering, University of Utah, Salt Lake City, Utah, USA. 6Department of Medical Pharmacology and Physiology,  
School of Medicine, University of Missouri School of Medicine, Columbia, Missouri, USA.  
7Division of Anatomic Pathology, Department of Pathology, University of Utah, Salt Lake City, Utah, USA.
Cerebral cavernous malformations (CCMs) are a common type of vascular malformation in the brain that 
are a major cause of hemorrhagic stroke. This condition has been independently linked to 3 separate genes: 
Krev1 interaction trapped (KRIT1), Cerebral cavernous malformation 2 (CCM2), and Programmed cell death 
10 (PDCD10). Despite the commonality in disease pathology caused by mutations in these 3 genes, we found 
that the loss of Pdcd10 results in significantly different developmental, cell biological, and signaling pheno-
types from those seen in the absence of Ccm2 and Krit1. PDCD10 bound to germinal center kinase III (GCKIII) 
family members, a subset of serine-threonine kinases, and facilitated lumen formation by endothelial cells 
both in vivo and in vitro. These findings suggest that CCM may be a common tissue manifestation of distinct 
mechanistic pathways. Nevertheless, loss of heterozygosity (LOH) for either Pdcd10 or Ccm2 resulted in CCMs 
in mice. The murine phenotype induced by loss of either protein reproduced all of the key clinical features 
observed in human patients with CCM, as determined by direct comparison with genotype-specific human sur-
gical specimens. These results suggest that CCM may be more effectively treated by directing therapies based 
on the underlying genetic mutation rather than treating the condition as a single clinical entity.
Introduction
Cerebral cavernous malformations (CCMs) are common vascular 
malformations with a prevalence of 1 in 200 to 250 individuals in 
unselected populations (1, 2). CCMs can lead to focal neurologi-
cal deficits, seizures, and hemorrhagic stroke, but no pharma-
cologic therapy currently exists (3). CCMs predominantly occur 
in the central nervous system and are characterized by subclini-
cal bleeding and consequential hemosiderin deposits that are 
detected by MRI (4). MRI is the primary clinical modality for 
detection, diagnosis, and management of CCMs. Hemosiderin 
deposits give CCMs an MRI appearance of a central mass with 
a dark perilesional halo, whose appearance is nearly diagnostic 
(pathognomonic) of cavernous malformation (5). Cavernous 
malformations are characterized by a complex of vascular chan-
nels of varying sizes lined by a single layer of endothelial cells 
without any abnormally large arteries, arterialized veins, or large 
venous outflow vessels. Although dense fibrillary neuroglial 
tissue may penetrate the mass, vascular channels are generally 
arranged in a back-to-back pattern with little or no intervening 
brain parenchyma. There is often a peripheral margin of gliotic 
tissue containing hemosiderin-laden macrophages (6).
CCMs can occur sporadically or be inherited in an autosomal 
dominant pattern. Familial CCM has been linked to heterozygos-
ity for any of 3 genes: Krev1 interaction trapped (KRIT1), Cerebral 
cavernous malformation 2 (CCM2), and Programmed cell death 
10 (PDCD10) (7). All 3 proteins bind each other in coimmuno-
precipitation experiments on cells overexpressing these proteins, 
leading to the hypothesis that they function as a complex to affect 
a common signaling mechanism (8). Both Krit1 and Ccm2 are 
required for proper connection of the developing heart with the 
aorta to establish circulation in the mouse embryo (9, 10). Mice 
lacking either Krit1 or Ccm2 fail to form a lumenized first bran-
chial arch artery to link the heart and aorta; as a result, mice lack-
ing either gene die at the same age. The requirement for Ccm2 is 
endothelial autonomous (9, 11). In the endothelium, both KRIT1 
and CCM2 suppress the activity of the small GTPase RhoA (9, 
12). Loss of either gene leads to RhoA activation and signaling 
through Rho kinase (ROCK) resulting in increased actin stress 
fibers, impaired cell-cell interactions, and increased vascular per-
meability (9, 12, 13). These defects can be reversed in cell culture 
and in mice with inhibitors of RhoA including HMG-CoA reduc-
tase inhibitors (statins) (9, 12).
A recent report suggested a similar mechanism of Rho activation 
for PDCD10 (14). However, other studies have suggested a different 
cell-signaling role for PDCD10. While KRIT1, CCM2, and PDCD10 
all occupy the cytoplasmic compartment of the cell, unique sub-
cellular localization for each has been described, including nuclear 
localization of KRIT1 (15) and Golgi localization of PDCD10 (16). 
Each protein has also been found to have unique binding partners 
(17–19). PDCD10’s binding partners include members of the germi-
nal center kinase III (GCKIII) subfamily of serine-threonine kinas-
es with homology to yeast sterile-20 (STE20) kinase (16, 20–23). 
Furthermore, the clinical features of CCM in KRIT1, CCM2, and 
PDCD10 families have important differences (24, 25), with PDCD10 
resulting in the most severe disease (24, 26). It is possible that CCM 
disease is the common result of multiple unique mechanisms and 
may require unique therapeutic strategies to target the underlying 
disturbed cellular and signaling pathways.
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Though the signaling and cellular mechanisms associated with 
the 3 known CCM proteins may be different, a common genetic 
mechanism of loss of heterozygosity (LOH) has been suggested 
for familial CCM disease (27–29). Familial CCM is more aggressive 
than sporadic disease, with an earlier age of onset, increased risk 
of hemorrhage and seizure, and an increased number of lesions (3, 
30–32). These observations have led to the hypothesis that CCM 
disease occurs by the Knudson 2-hit mechanism, similar to retino-
blastoma (33). There is limited evidence from human pathologic 
specimens to support an association of LOH with CCM lesions. 
In a series of challenging experiments, a number of investigators 
have identified biallelic mutations, 1 somatic and 1 germline, in 
the endothelium of a subset of patient samples (27, 28, 34). While 
LOH could not be confirmed for a number of samples, a total of 
4 cases have been described for KRIT1 and 1 case each for CCM2 
and PDCD10. Mice heterozygous for Krit1 or Ccm2 do not develop 
cavernous malformations, and no examples of secondary somatic 
mutations have been reported (35, 36).
To determine whether endothelial LOH is not simply associ-
ated with, but is causative for, CCM pathology, requires an animal 
model with a controlled genetic mutation that can be directed and 
detected in a tissue-specific manner. In this work, we use drug-
inducible, tissue-specific strains of Cre recombinase to target 
conditional null alleles of the CCM genes to test directly the 2-hit 
hypothesis for cavernous malformations. We demonstrate that 
Pdcd10 differs substantially from Ccm2 in development, cell biol-
ogy, and signaling, yet LOH is the common genetic mechanism 
to cause CCMs in both genotypes. These findings suggest that 
PDCD10 influences different endothelial signaling pathways from 
KRIT1/CCM2 to lead to a common histopathology and imply that 
medical treatment to stabilize familial CCM may need to be devel-
oped and evaluated in a genotype-specific manner.
Results
Loss of Pdcd10 results in embryonic lethal phenotypes distinct from loss of 
Krit1 or Ccm2. To determine the role of Pdcd10 in development and 
disease, we developed a conditional null allele, Pdcd10flox, in which 
exons 4–8 are flanked with LoxP sites (Supplemental Figure 1; sup-
plemental material available online with this article; doi:10.1172/
JCI44393DS1). This strategy also allowed us to generate a consti-
tutive null allele, Pdcd10–, by crossing mice carrying Pdcd10flox with 
a mouse strain expressing Cre recombinase in the germline (37). 
To characterize the role of Pdcd10 in development, we intercrossed 
Pdcd10+/– mice and harvested embryos at varying stages of devel-
opment. Surprisingly, we found that mice lacking Pdcd10 died at 
a much earlier age than those deficient for either Krit1 or Ccm2. 
Whereas Krit1 and Ccm2 mice show growth arrest at E9.0 and die 
at E11 (9–11), the loss of Pdcd10 leads to growth arrest at E8.0, after 
gastrulation, but prior to the onset of circulation or the requirement 
for cardiovascular function (Table 1 and Supplemental Figure 1).
An earlier requirement for Pdcd10 than Krit1 or Ccm2 in devel-
opment does not preclude a shared role in the vascular system. 
Mice with endothelial loss of Ccm2 phenocopy the constitutive 
null mutant (9, 11), so we sought to determine whether mice with 
endothelial loss of Pdcd10 would also recapitulate the Ccm2 phe-
notype. Using the endothelial Tie2-Cre driver, the same Cre driver 
that we used to ablate Ccm2 (9), we found that although mice with 
endothelial loss of Pdcd10 (Pdcd10flox/–;Tie2-Cre) did not survive to 
birth, they had patent branchial arch arteries, a developed circula-
tory system, and were indistinguishable from control littermates at 
E9.5 (Supplemental Figure 2). Instead, we found that loss of Pdcd10 
in the endothelium leads to progressive enlargement of the cardi-
nal vein and other veins of the rostral embryo at E11.5 (Figure 1). 
Venous enlargement was not due to abnormal cardiac structure or 
function (Figure 1 and Supplemental Figure 2), nor were defects 
observed in arteries of the embryo (Figure 1 and Supplemental 
Figure 2). Death occurred due to hemorrhage from venous rup-
ture by E13.5 (Table 2). Additionally, mice with loss of Pdcd10 in 
neural and glial tissues induced by Nestin-Cre showed no vascular 
or any other obvious defects and were born alive (Supplemental 
Figure 2 and Supplemental Table 1). These observations suggest 
that Pdcd10 is required in the endothelium for control of venous 
size and integrity, yet Pdcd10 differs from Ccm2 in that it is not 
required for the establishment of circulation.
Loss of PDCD10 does not affect RhoA signaling but results in lumen for-
mation defects. To explore the role of PDCD10 in endothelial cells, 
we depleted PDCD10 in human dermal microvascular endothelial 
cells (HMVEC) with siRNA (Supplemental Figure 3). Whereas the 
loss of CCM2 leads to an increase in actin stress fibers as a result 
of RhoA activation (9, 12, 13) and phosphorylation of myosin light 
chain-2 by Rho kinase (Figure 2), we observed none of these indica-
tors of RhoA activation with the loss of PDCD10 (Figure 2). Thus, 
the role of PDCD10 in endothelial cell biology and signaling dif-
fers from that of CCM2.
Having found that PDCD10’s function in development differs 
from that of CCM2, we sought to identify defects associated with 
PDCD10 depletion in assays relevant to vascular development. 
PDCD10-depleted HUVECs showed defective function in a 3D 
angiogenesis assay. Endothelial cells plated in a collagen matrix 
spontaneously organize into complex multicellular capillary-like 
networks with lumens (38), but cells depleted of PDCD10 failed 
to organize themselves into a lumenized network (Supplemental 
Figure 4, A and B). We explored potential downstream signaling 
pathways using this assay. A growing body of evidence suggests 
that PDCD10 interacts with the GCKIII subfamily of serine-threo-
nine kinases (16, 21–23); we used siRNA to deplete cells of each of 
the subfamily members (Supplemental Figure 3). We observed no 
effect on lumen formation with the knockdown of STK25, STK24, 
or MST4 in HUVECs (Supplemental Figure 4C).
Pdcd10 functionally associates with GCKIII in lumen formation. Because 
the GCKIII family members may be functionally redundant, we 
sought to validate the importance of the PDCD10-GCKIII interac-
tion in vivo and in a simpler genetic model. We chose the fruit fly, 
Drosophila melanogaster, in which the GCKIII family is represented by 
Table 1
Early growth arrest and death in embryos lacking Pdcd10
Cross  Pdcd10+/– × Pdcd10+/–
Genotype Pdcd10+/+ Pdcd10+/– Pdcd10–/– Total litters
No. of progeny
E7.5 75 114 52 27
E8.0 9 13 0A 4
E8.5 27 45 0A 13
E9.0 1 5 0 1
>E9.0 7 8 0 3
The numbers of normal-appearing and viable offspring by genotype in 
matings between Pdcd10+/– parents are shown. AAges at which growth-
arrested embryos could be obtained.
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a single protein, GCKIII. This model avoids the complexity of human 
or mouse, which has 3 GCKIII kinases, or zebrafish, which has 2 
orthologs for Pdcd10, 2 orthologs for STK25, and single orthologs for 
STK24 and MST4 (23). Furthermore, the Drosophila genome contains 
a single ortholog of PDCD10, but no orthologs for KRIT1 or CCM2. 
Thus, Drosophila represents a simple model organism for studying 
Pdcd10-specific biology. To ensure that the biochemical interaction 
between PDCD10 and GCKIII was conserved in Drosophila, we per-
formed immunoprecipitation assays with the Drosophila proteins. 
Drosophila Pdcd10 binds to GCKIII (Supplemental Figure 4D) in a 
manner analogous to that of human, mouse, or zebrafish protein 
(21, 23). A human disease PDCD10 mutation exists, which deletes 
18 amino acids crucial for PDCD10-GCKIII binding (21). Removal 
of the analogous 18 amino acids from the Drosophila Pdcd10 protein 
abrogated binding to GCKIII (Supplemental Figure 4D).
Whereas Drosophila do not develop a vascular system, they do form 
a branched, lumenized network of tubes in the tracheal (respira-
tory) system. This epithelial network requires coordinated cell-cell 
interactions and specialized cell-cell junctions, 
analogous to the mammalian vascular system 
(39, 40). To determine the necessity of Pdcd10 
in developing fly tracheal tubes, we expressed a 
dsRNA directed against Pdcd10 (41) under the 
control of the tracheal-specific Breathless pro-
moter (42) using the GAL4-UAS system (43). 
We found that tracheal tubes lacking Pdcd10 
grow and branch normally, but fail to lumen-
ize and fill with air (Supplemental Figure 5), 
indicating that Pdcd10 is required for normal 
lumen formation in fly tracheal tubes as it is in 
human endothelial tubes. This effect is highly 
penetrant; nearly all dsRNA-expressing flies 
show lack of lumenization in multiple tracheal tubes 
(Supplemental Figure 4E). The specificity of this effect 
is confirmed, as it could be rescued by coexpression 
of Drosophila Pdcd10 in RNAi-expressing cells (Sup-
plemental Figure 4E). Notably, coexpression of the 
18–amino acid deletion form of Drosophila Pdcd10, 
which does not bind to GCKIII, fails to rescue this phe-
notype (Supplemental Figure 4E). We used the same 
RNAi strategy to inactivate GCKIII (44) in the devel-
oping tracheal system. Tracheal tubes lacking GCKIII 
exhibit failure of lumenization (Supplemental Figure 5), 
and the phenotype appears very similar to that of 
Pdcd10-deficient tubes. Thus, Pdcd10 is essential for normal lumen 
formation in the absence of Krit1 and Ccm2 and in a manner that 
requires interaction with GCKIII kinases.
Our experiments in Drosophila suggested that GCKIII kinases 
are required for lumen formation but that functional redundancy 
in mammalian cells may have accounted for the lack of a lumen 
formation defect when any single kinase was lost. We therefore 
performed combinatorial knockdown experiments for pairs of the 
GCKIII kinases. Consistent with our hypothesis, we found that the 
loss of STK25, if coupled with the loss of either STK24 or MST4, 
was sufficient to reproduce the lumen formation defects seen with 
PDCD10 depletion (Supplemental Figure 4). Thus, PDCD10 inter-
action with GCKIII kinases is critical in lumen formation.
LOH of either Pdcd10 or Ccm2 causes murine cavernous malformations 
that phenocopy human CCMs. Pdcd10 and Ccm2’s functions clearly 
differ in embryonic development, in endothelial cell culture, and 
in signaling, and Pdcd10 is necessary for lumen formation in a 
system that lacks Ccm2 or Krit1. The 3 genes, however, are linked 
Figure 1
Pdcd10 is required in the endothelium for venous integ-
rity. (A–H) H&E staining of developmental time course 
of Pdcd10 endothelial knockout. Pdcd10flox/+;Tie2-Cre 
is shown in A–D. Pdcd10flox/–;Tie2-Cre is shown in E–H. 
Close-up images of the cardinal vein at E12.5 are shown in 
D and H. Asterisks denote the cardinal veins. Circles denote 
the external jugular veins. (I and J) Echocardiography of 
hearts from Pdcd10flox/– (I) and Pdcd10flox/–;Tie2-Cre (J) 
mice at E11.5. Top panels show M-mode images of hearts 
contracting over time. Bottom panels show waveforms cor-
responding to blood flow across the atrioventricular valves. 
s, systole; d, diastole; e, early filling; a, atrial contraction; R, 
valvular regurgitation. Scale bars: 1 mm (A–C and E–G); 
500 μm (D and H). n ≥ 6 embryos at each age.
Table 2
Loss of Pdcd10 in the endothelium leads to embryonic death after E12.5
Cross  Pdcd10flox/flox × Pdcd10+/–;Tie2-Cre
Genotype Pdcd10flox/+ Pdcd10flox/– Pdcd10flox/+;Tie2-Cre Pdcd10flox/–;Tie2-Cre
No. of progeny
E9.5 14 14 7 11
E12.5 13 28 16 16
E15.5 8 8 20 0
P21 26 20 20 0
Live offspring by genotype at embryonic and postnatal time points resulting from matings 
between Pdcd10flox/flox and Pdcd10+/–;Tie2-Cre parents.
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to the same human disease. Limited human genetics suggested 
an association between LOH and CCM disease, so we investigated 
whether Pdcd10 and Ccm2 share this genetic mechanism for causing 
disease. To control the timing of the endothelial “second-hit,” we 
used a drug-inducible Cre strain under the control of the PDGF-B 
promoter. This PDGFb-iCreERT2 strain expresses a Cre recombinase 
activated only after administration of the drug tamoxifen. Con-
sistent with the original report describing this recombinase (37), 
we found that the administration of tamoxifen on the first post-
natal day (P1) led to efficient, endothelial-specific recombination 
throughout the entire brain vasculature (Supplemental Figure 6). 
The induction of endothelial LOH of either Pdcd10 or Ccm2 by this 
Cre at birth resulted in CCMs in mice as early as 1 month of age 
(Figure 3). Induction of endothelial LOH of either Pdcd10 or Ccm2 
resulted in a spectrum of vascular malformations, from capillary 
telangiectasias, to isolated caverns, to multiple back-to-back cav-
erns with thrombosis, hemorrhage, and formation of secondary 
channels (Supplemental Figure 7). Loss of protein product via 
LOH was confirmed by antibody staining (Supplemental Figure 8). 
The retinal vasculature is another location for human CCMs, and 
murine cavernous malformations were also observed in mouse ret-
inal vasculature (Supplemental Figure 9). To formally prove LOH 
in the endothelium of these CCMs, we performed laser capture 
microdissection to obtain tissue-specific DNA as previously done 
in human studies of CCM (28). We found that DNA from lesion 
endothelium had lost the conditional allele for either Pdcd10 or 
Ccm2, confirming LOH, whereas this allele could still be detected 
in adjacent neuronal tissue (Figure 3). In contrast, loss of Ccm2 in 
neural tissues using Nestin-Cre did not result in the development 
of vascular malformations (Supplemental Figure 10).
We characterized the histopathologic features of cavernous 
malformations in mice with induced endothelial loss of either 
Pdcd10 (Figure 4) or Ccm2 (Figure 5). We compared mouse CCMs 
with surgical specimens from CCM patients with germline muta-
tions of either PDCD10 (Figure 4) or CCM2 (Figure 5). Cavernous 
malformations in these induced mouse models share all of the 
key histologic features of CCM lesions with human specimens. 
Furthermore, both Pdcd10 and Ccm2 resulted in identical patho-
logic findings for all of these defining characteristics in both 
human and mouse (Table 3). Mouse specimens showed numerous 
Figure 2
PDCD10 differs from CCM2 in downstream signaling. (A) 
Phalloidin staining of human microvascular endothelial cells 
treated with siRNA directed against CCM2, PDCD10, or non-
sense control. (B) Quantification of stress fiber response of 
HMVEC cells. Stress fiber content is determined by adding 
the total length of stress fibers divided by the total number of 
cells. Results indicate mean ± SEM and are representative of 
at least 3 independent experiments. *P < 0.001 versus con-
trol or PDCD10; **P = NS versus control. (C) Immunoblot for 
phospho-myosin light chain-2 (with α-actinin immunoblot as a 
loading control). Results are representative of 3 independent 
experiments. Scale bars: 100 μm.
Figure 3
Cavernous malformations result from LOH of 
either Ccm2 or Pdcd10. (A) Cavernous malfor-
mation (arrow) shown in an H&E-stained section 
of brain cerebrum from a mouse with induced 
endothelial knockout of Ccm2. (B) Confirmation 
of LOH of Ccm2 in 2 mice with loss of Ccm2flox 
allele by PCR, compared with Pdcd10 wild-type 
allele as a control. (C) Cavernous malforma-
tions (arrows) and a less complex telangiectasia 
(arrowhead) shown in an H&E-stained section 
of brain cerebrum from a mouse with induced 
endothelial knockout of Pdcd10. (D) Confirma-
tion of LOH of Pdcd10 in 2 mice by PCR with 
loss of Pdcd10flox allele compared with Ccm2 
wild-type allele as a control. Samples in B and D 
were obtained via laser capture microdissection 
of sectioned mouse brains. Scale bars: 1 mm.
32
research article
 The Journal of Clinical Investigation   http://www.jci.org   Volume 121   Number 5   May 2011 1875
vascular channels of variable diameter (Figure 4, A and B, and 
Figure 5, A and B), some of them with organized thrombi. 
Immunohistochemical stains for endothelium highlighted 
endothelial cells in the channels, with focal attenuation or loss 
of endothelial cells in larger channels (Figure 4, G and H, and 
Figure 5, G and H). Iron stain highlighted the presence of hemo-
siderin-laden macrophages and hemosiderin in the wall of the 
channels as well as in the periphery and brain tissue (Figure 4, C 
and D, and Figure 5, C and D). Additionally, we also examined 
gliosis, trichrome staining, elastin, laminin, and collagen type IV, 
and these features were all identical between mouse and human 
lesions (Figure 4, E and N, Figure 5, E and N, and Table 3).
We also examined mouse lesions at the ultrastructural level using 
transmission electron microscopy. Murine cavernous malformations 
showed endothelial cells lining vascular channels with associated basal 
lamina (Figure 6A). Some of the larger channels showed segmental 
multilayering (lamellated appearance) of the basal lamina (Figure 6B). 
The most dilated channels showed focally marked attenuation of the 
endothelial cells (Figure 6C); however, tight junctions were identified 
between cells, and definitive gaps were not seen. Connective tissue 
composed mainly of collagen fibers separated the vascular channels 
(Figure 6D). Pericytes or astrocytic foot processes were missing, as 
seen in human lesions. Foci of mononuclear inflammatory cells were 
also seen (Figure 6E), including hemosiderin-laden macrophages (Fig-
ure 6F). Ultrastructural analysis of murine CCM lesions was similar to 
that described in human CCMs (45), further solidifying the fidelity of 
the mouse model to the human disease.
Murine cavernous malformations can be detected and followed noninva-
sively by MRI. MRI is used to document the natural history of human 
cavernous malformations and will be necessary for prospective thera-
peutic trials in both mice and humans. We thus employed monthly 
live MRI studies to follow the onset and progression of disease in 
mice until at least 6 months of age (Figure 7). As in humans (24), 
mice lacking Pdcd10 had an earlier onset of disease, with a more 
severe phenotype than Ccm2. All Pdcd10 mice studied at 1 month of 
age had lesions, whereas no Ccm2 mice had yet developed lesions by 2 
months of age (Figure 7K). Mice with Pdcd10 mutations had a greater 
disease burden when assessed by total lesion burden (Figure 7L) or 
by number of complex lesions (increased signal intensity within the 
lesion; Figure 7M). Cavernous malformations were fully penetrant 
in mice with Ccm2 LOH at 6 months of age and most had lesions at 
4 months, at which time the disparity between the genotypes began 
to narrow. This parity reflected not only the increased burden of dis-
ease in Ccm2, but also the onset of death in the most severely affected 
Pdcd10 mice. Mice of both genotypes began to die of hemorrhage, 
but mortality was greater in mice with LOH for Pdcd10 (Figure 7N), 
a finding that reflects the reported experience in humans (24).
Discussion
Although CCM has been associated with mutations in 3 distinct 
loci, it has been clinically treated as a single pathophysiologic entity. 
In this manuscript, we describe for what we believe is the first time 
the pathologic features of CCM in a genotype-specific manner. We 
Figure 4
Pathologic analysis of mouse and human PDCD10-associated CCM. 
Paired analysis of histologic sections with human tissue on the left and 
mouse on the right. (A and B) H&E staining revealing back-to-back 
vascular channels (arrows) and hemosiderin pigment (arrowheads) in 
surrounding tissues. (C and D) Iron (blue) detected by Prussian blue 
stain highlights hemosiderin deposits in macrophages and surrounding 
brain tissue. (E and F) Fibrous matrix deposits (blue) identified by Mas-
son’s trichrome staining with fibrous tissue surrounding vascular chan-
nels (arrows) and in surrounding gliotic brain. (G and H) Endothelial 
staining for CD34 (G) or CD31 (H) is positive in the cells lining the 
channels. (I and J) Elastin staining shows that vascular channels lack 
elastic laminae (arrows) unlike normal vessels of similar caliber (arrow-
head, inset in I). The fibrous matrix surrounding channels includes lam-
inin (K and L) and collagen IV (M and N). Scale bars: 200 μm.
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find that mutations of both PDCD10 and CCM2 result in a com-
mon pathologic expression of disease in both humans and mice. 
Surprisingly, this common disease endpoint does not constitute 
proof of a common disease mechanism. Whereas our previous work 
and the work of others found that Ccm2 and Krit1 play similar roles 
in embryonic development, in vitro cell biology, and cell signaling 
(9, 10, 12, 13), these roles differ from those we observe with Pdcd10. 
Unlike Krit1 and Ccm2, Pdcd10 is not required for development 
of the branchial arch arteries that connect the heart to the aorta. 
Rather, Pdcd10 has an essential, nonendothelial role in develop-
ment not shared with Krit1 or Ccm2 as well as an essential function 
in venous maturation. We further observe differences in cell biol-
ogy and signaling between PDCD10 and KRIT1 or CCM2; whereas 
the loss of KRIT1 or CCM2 leads to RhoA activation, increased Rho 
kinase activity, myosin light chain phosphorylation, and actin stress 
fiber formation (9, 12, 13), we do not observe activation of this sig-
naling pathway in cells depleted of PDCD10. Instead, we found that 
PDCD10 signals primarily through the GCKIII family of kinases.
The similarity in human CCM disease caused by mutations in 
KRIT1, CCM2, and PDCD10 have led to an assumption that the 
proteins encoded by these genes function in a common signal-
ing pathway. This assumption has been supported by experi-
mental evidence showing binding between ectopically expressed, 
epitope-tagged proteins (7, 8). However, the complexities of sig-
naling pathways and pathophysiology allow for multiple mecha-
nisms to converge on a common disease phenotype (Figure 8A). 
An example is hypertrophic cardiomyopathy, which was consid-
ered 1 disease until molecular genetics revealed that 2 different 
mechanisms (sarcomere function or metabolism), each affected 
by distinct genes, both result in pathologic hypertrophy (Figure 
8B and ref. 46). We propose that a similar scenario is involved in 
the pathogenesis of CCM (Figure 8C).
There is controversy concerning the signaling pathways affect-
ed by PDCD10. Several reports suggest an essential role for bind-
ing GCKIII family serine-threonine kinases (16, 21–23). However, 
a recent characterization of mice carrying a different conditional 
allele of Pdcd10 showed that the loss of Pdcd10 in endothelial 
cells substantially blocks VEGFR2 signaling and inhibits the ear-
liest stages of developmental angiogenesis (47). The implication 
of VEGFR2 signaling through MAP kinases agrees with a previ-
ous report linking GCKIII kinases and ERK signaling (20). Our 
data contrast with these reports; we observe that the absence of 
Pdcd10 in vivo leads to a localized vascular defect at a much later 
developmental stage, inconsistent with a panendothelial block 
of VEGF signaling. In cell culture, we have not found any inter-
action between PDCD10 and VEGF or ERK signaling (Supple-
mental Figure 11). We suspect that this disparity may be due to a 
difference in knockout strategy; however, our confidence in our 
allele is bolstered by our ability to induce CCM disease. Our data 
support the model that PDCD10 signals through the GCKIII 
family kinases, as we have observed in human endothelial cells 
and in Drosophila that PDCD10 binds to GCKIII family kinases 
and both are required for lumen formation. Previous reports have 
further suggested that GCKIII signals through RhoA to converge 
Figure 5
Pathologic analysis of mouse and human CCM2-associated CCM. 
Paired analysis of histologic sections with human tissue on the left and 
mouse on the right. (A and B) H&E staining revealing back-to-back vas-
cular channels (arrows) and hemosiderin pigment (arrowhead) in sur-
rounding tissues. (C and D) Iron (blue) detected by Prussian blue stain 
highlights hemosiderin deposits in macrophages and surrounding brain 
tissue. (E and F) Fibrous matrix deposits (blue) identified by Masson’s 
trichrome staining with fibrous tissue surrounding vascular channels 
(arrows) and in surrounding gliotic brain. (G and H) Endothelial stain-
ing for CD34 (G) or CD31 (H) is positive in the cells lining the channels. 
(I and J) Elastin staining shows that vascular channels lack elastic 
laminae (arrows). The fibrous matrix surrounding channels includes 
laminin (K and L) and collagen IV (M and N). Scale bars: 200 μm.
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with KRIT1/CCM2 signaling (23). By direct comparison of Ccm2 
and Pdcd10 in mouse and cell biology, however, our data suggest 
that PDCD10 signaling is distinct from the CCM2-RhoA axis.
The nature and severity of disease in familial forms of CCM in 
comparison with sporadic CCM suggested a genetic mechanism 
consistent with Knudson’s 2-hit hypothesis (33): LOH for a CCM 
gene induces lesions. Limited evidence to support this theory has 
come from a few human surgical samples amid multiple cases in 
which the second genetic hit could not be found (27, 28). Further 
supportive evidence comes from mice with heterozygous mutations 
for Krit1 or Ccm2 that have been mated into strains with high rates 
of spontaneous mutations. Mice heterozygous for Krit1 develop 
CCM lesions on either a p53- or Msh2-null background, whereas 
mice heterozygous for Ccm2 develop lesions only on the p53-, but 
not the Msh2-null background (35, 36). Whereas these models 
provide suggestive evidence of LOH and employ stochastic events 
to induce CCM formation, LOH was not demonstrated at either 
locus, nor can the LOH hypothesis be supported for all CCM genes, 
as Ccm2+/–;Msh2–/– mice do not develop CCMs. These models also 
do not rule out a role for mutations in other, non-CCM genes and 
do not control tissue specificity of mutation. The penetrance of 
CCMs in these models is incomplete, complicating the use of these 
models in prospective trials to study therapeutics or natural history 
of CCM disease. Concurrent development of neoplasms in both 
the p53- and the Msh2-null backgrounds also adds confounding 
physiological stressors and increases the mortality of the animals. 
In contrast, we employ a strategy that allows direct testing of the 
LOH mechanism in CCM disease. Using an inducible 
Cre-recombinase, we have targeted gene-specific LOH 
for both Pdcd10 and Ccm2 to the endothelium of mice. 
In the case of both genes, we have found that LOH is 
sufficient to cause a fully penetrant CCM phenotype 
that recapitulates every key pathologic and radiologic 
hallmark of human disease.
Much work remains to translate the observations 
and insights regarding disease signaling mechanisms 
into viable therapeutic strategies in patients. This work 
underscores the importance of carefully considering 
disease mechanisms in a genotype-specific manner. The 
availability of faithful, genotype-specific, and highly 
penetrant mouse models of CCM disease unlocks the 
tremendous opportunities to study the natural his-
tory of lesion genesis and progression as well as opportunities for 
preclinical testing of therapeutic interventions. In order for mouse 
models of CCM disease to be useful in informing human studies, 
the same tools used to follow patients with CCM need to be devel-
oped for serial observation of affected mice. We have demonstrated 
that noninvasive MRI of live mice, the same modality used to follow 
CCM in humans, can detect and follow murine CCMs. Although 
our mouse models share a measurable mortality, as with humans, 
they are compatible with prolonged survival and serial, noninvasive 
observation. The ability to follow these mice noninvasively over time 
is a crucial prerequisite for judging the effectiveness of any preclini-
cal therapeutic strategy in the future and for testing the timing and 
intensity of LOH required for lesion formation. Our mouse models 
of CCM phenocopy human disease closely, supplanting previously 
available surrogate phenotypes, and are a powerful new tool in the 
armamentarium to decipher and combat CCM disease.
Methods
Mouse strains. The Ccm2 conditional knockout mice have been previ-
ously described (9). A construct for the conditional allele of Pdcd10 was 
derived from genomic sequence obtained from a BAC clone (RP22 library; 
Invitrogen). The construct extended from a SacII site 5′ of exon 4 through 
an ApaI site 3′ of exon 8. The construct contained inserts as outlined in 
Supplemental Figure 1, including LoxP sequences at a KasI site just 5′ of 
exon 4 and at a EcoRI site just 3′ of exon 8. All mice were backcrossed into 
the C57BL/6J strain. Experiments performed prior to the fifth cross were 
performed with littermate controls. LacZ reporter mice (R26R1), Tie2-Cre 
Table 3
Pathologic findings in human and murine CCMs
Genotype Human CCM2 Murine Ccm2 Human PDCD10 Murine Pdcd10
Trichrome + + ++ ++
Iron + + ++ ++
Elastin – – – –
CD34 + NA + NA
CD31 NA + NA +
Laminin + + + +
Collagen IV + + + +
The pathologic findings compared for human and murine CCMs associated with  
mutations of either CCM2 or PDCD10.
Figure 6
Ultrastructural findings in murine cavernous malformations. 
(A) Dilated vascular channels are lined by endothelial 
cells (arrowheads) with associated basal lamina (arrows). 
(B) Occasional channels have segments with a multilay-
ered appearance (arrows indicate lamellae of endothe-
lium with basal laminae). Tight junctions appear intact 
(arrowhead). (C) Focal areas of endothelial attenuation 
are observed (arrow) without apparent gaps or disruption 
of tight junctions (arrowhead indicates a junctional com-
plex). (D) Channels are separated by loose connective 
tissue composed mostly of collagen (arrows). (E) Foci of 
mononuclear inflammatory cells are present (arrows). (F) 
Hemosiderin-laden macrophages (arrow) are among the 
inflammatory cells observed. Images are representative of 
5 lesions from 3 Pdcd10 mice. Scale bars: 4 μm.
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mice, and PDGFb-iCreERT2 mice were generously provided by Phil Soriano 
(Fred Hutchinson Cancer Research Center, Seattle, Washington, USA, and 
Mount Sinai School of Medicine, New York, New York, USA), Masashi 
Yanagisawa (University of Texas Southwestern Medical Center at Dallas, 
Dallas, Texas, USA), and Marcus Fruttiger (University College London 
Institute of Ophthalmology, London, United Kingdom) via Holger Ger-
hardt (London Research Institute — Cancer Research UK, London, United 
Kingdom), respectively. HPRT-Cre, Nestin-Cre, and Tomato-EGFP reporter 
mice were obtained from The Jackson Laboratory. Genotypes were deter-
mined by PCR analysis of genomic DNA isolated from either ear biopsies 
or yolk sac tissues using primers outlined in Supplemental Figure 1. Prim-
er sequences were as follows: primer W: 5′-GCAATCCATCTTGTTCAAT-
GGC-3′, primer X: 5′-CGTAGGTCAGGGTGGTCACG-3′, primer Y: 
5′-TGAAAGAGGACATACTGGAGAGGC-3′, prim-
er Z: 5′-AAGGACAAGAAAGCACTGTTGACC-3′. 
Tamoxifen (Sigma-Aldrich) was resuspended in 
corn oil (Sigma-Aldrich), and 40 ng was given as an 
i.p. injection to mouse pups on perinatal day 1.
MRI of mouse brains. All MRI experiments were con-
ducted on a 7T Bruker Biospec 70/30 USR scanner 
(Bruker Biospin MRI Inc.) equipped with a BGA12S 
gradients set. A combination of volume-transmit–
only radio frequency coil (internal diameter: 72 mm) 
and a quad-surface-receive–only coil (internal diam-
eter: 1.5 cm) were used. For live scans, mice were 
anesthetized in 2.5% isoflurane and then placed into 
the scanner on top of circulating heated water. Dur-
ing the scans, mice were monitored for temperature 
and respiration, with isoflurane concentration and 
water bath temperature adjusted to maintain a body 
temperature between 35.8°C and 37.6°C and respi-
ration between 75 and 100 breaths/min. A gradient 
recalled echo sequence was used to acquire coronal 
slices spanning the whole brain. Sequence param-
eters were as follows: repetition time, 328 ms; echo 
time, 5.4 ms; flip-angle, 40°; 12 averages, in-plane-
resolution, 125 μm × 125 μm; and slice thickness, 0.5 mm.
For postmortem specimens, mouse skulls were fixed in 4% formaldehyde 
for at least 3 days before the brain was imaged with the skull intact. Post-
mortem MRI scanning allows a high-resolution coverage of the brain at 
the expense of longer scan time. High-resolution 3D gradient echo was 
acquired using the same scanner configuration described above, with iso-
tropic voxel size of 78 μm × 78 μm × 78 μm over 9 hours. Other sequence 
parameters were as follows: repetition time, 250 ms; echo time, 7.5 ms; flip 
angle, 30°; and 2 averages.
Histology. Embryo and mouse CCM lesions were studied with antibodies 
to PECAM (1:250 dilution, clone MEC13.3; BD Biosciences) and PDCD10 
(1:50 dilution, Prestige Antibody; Sigma-Aldrich). Improved visualization 
on paraffin sections was obtained using a biotinylated tyramide signal 
Figure 7
Natural history of murine CCM by MRI — Pdcd10 
onsets earlier and is more severe than Ccm2. 
(A–D) Live MRI scans of the same Pdcd10flox/+; 
PDGFb-iCreERT2 mouse at 2 months and 3 
months (A and B) and its Pdcd10flox/–;PDGFb-
iCreERT2 littermate (C and D). Both mice were 
given tamoxifen at birth. (E–J) Live MRI scans 
of the same Ccm2flox/+;PDGFb-iCreERT2 mouse 
(E–G) and its Ccm2flox/–;PDGFb-iCreERT2 lit-
termate (H–J) at 4, 6, and 7 months. Both mice 
were given tamoxifen at birth. Arrows indicate 
CCM lesions. (K) Disease penetrance (pro-
portion affected) by age in Ccm2 and Pdcd10 
induced knockout mice as assessed by live MRI. 
(L) Lesion burden assessed as total number 
of lesions observed on each tomographic view 
(slice) of the MRI per mouse. (M) Number of 
complex lesions (lesions with bright cores) per 
mouse. (N) Kaplan-Meier survival curve of Ccm2 
and Pdcd10 induced knockout mice. For K–N, 
n = 11 Ccm2, n = 13 Pdcd10. Data in L and M 
represent mean ± SEM. *P < 0.01; **P < 0.05; 
***P < 0.001. Scale bars: 1 mm.
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amplification (TSA) kit (PerkinElmer) according to the manufacturer’s 
instructions. To demonstrate tissue specificity of PDFGb-iCreERT2, brains 
from mice carrying a LacZ reporter allele were fixed and then stained 
with X-gal as previously described (48). Brains from mice carrying the 
Tomato-EGFP reporter allele were fixed and then embedded into OCT (Fish-
er Scientific) for fluorescent frozen sections. H&E staining of embryos was 
performed using standard procedures.
For histology of adult mouse brains, mouse skulls were fixed in 4% form-
aldehyde for at least 3 days or zinc-buffered formalin overnight before the 
brain was removed and sliced into 4 coronal sections. These sections were 
embedded into paraffin by standard techniques. Prussian blue staining 
for iron and Masson’s trichrome staining of mouse brain sections were 
performed using the Artisan system (DAKO) according to manufacturer’s 
instructions. Staining for elastin, laminin, and collagen IV was performed 
by the Immunohistochemistry Research and Development Lab at ARUP 
Laboratories. Human CCM samples were stained in the same way as adult 
mouse brains except for CD34 staining, which was performed by the Cen-
tral Labs at Intermountain Medical Center (Murray, Utah, USA).
Fluorescent staining of mouse retinas. Mice were anesthetized using Avertin 
(2,2,2-tribromoethanol, 0.4 mg/g; Acros Organics) and perfused with fluo-
rescently conjugated tomato lectin (Vector Labs) as previously described 
(49) at a dose of 5 μg/g body weight. After 5 minutes, mice were perfused 
with saline and then with 4% formaldehyde. Retinas were then extracted, 
stained, and mounted as previously described (50).
Analysis of mouse embryos. Confocal immunofluorescence of embryos and 
fetal ultrasound were performed as previously described (9).
Transmission electron microscopy. Samples were fixed in 1% formaldehyde, 
2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer with 8 mM CaCl2 
and 2.4% sucrose, pH 7.4, for at least 3 days. Samples were then rinsed in 
0.1 M cacodylate buffer, postfixed in 2% osmium tetroxide in 0.1 M caco-
dylate buffer, rinsed in type I water, and then enbloc stained with satu-
rated aqueous uranyl acetate. Samples were dehydrated through a graded 
series of ethanols, followed with final dehydration in acetone, and then 
infiltrated and embedded in an epoxy resin.
Thick sections and thin sections were cut on a Leica EM UC6 ultramicro-
tome (Leica Microsystems). The thick sections were cut with glass and the thin 
sections were cut with a diatome diamond knife. Thick sections were dried on 
glass slides and were stained with 1% toluidine blue O in 1% aqueous sodium 
borate. Thin sections were placed on 135 mesh copper hex grids and stained 
sequentially with saturated aqueous uranyl acetate and Reynolds lead citrate.
Sections were examined on an FEI Tecnai T-12 transmission electron 
microscope (FEI) at 80 KV. Images were taken on Kodak 4489 electron 
microscope film, developed with Kodak D-19 developer, fixed, washed, 
and dried. The negatives were scanned on an Epson Perfection Photo 4990 
flatbed scanner.
Cell culture. HUVEC and HMVEC were obtained from Lonza and grown 
according to the manufacturer’s instructions in EGM-2 media (HUVEC) or 
EGM-2MV media (HMVEC). Human embryonic kidney (HEK 293T) cells 
(ATCC) were grown in DMEM (Gibco; Invitrogen) with 10% fetal bovine 
serum (Bio-West) supplemented with antibiotics. EAHY cells were generously 
provided by Andrew Weyrich (University of Utah) and were grown in DMEM 
with 10% fetal bovine serum and HAT supplement (Sigma-Aldrich).
Transfection of ECs with siRNAs. Human CCM2 and PDCD10 siRNAs were 
obtained from Dharmacon. Luciferase GL2 duplex or nontargeting siRNA 
(Dharmacon) were used as controls. EC transfection with siRNAs was car-
ried out in growth media with 1% serum. Details of the siRNA transfection 
protocol have been described previously (51).
RT-PCR. Total RNA was extracted from EC vasculogenesis assay at indi-
cated time points or from siRNA-treated ECs using the ToTALLY RNA 
Isolation Kit (Ambion) according to the manufacturer’s instructions. RNA 
(1 μg) was reverse transcribed using AccuScript High Fidelity 1st strand 
cDNA synthesis kit (Stratagene; Agilent). RT-PCR amplification used 
the following primers: forward: 5′-AGACTTCACGGAGTCCCTTC-3′, 
reverse: 5′-AGAAGGTCTGAAGTATTAAGTTGG-3′. For quantitative 
real-time PCR, total RNA was extracted from cultured endothelial cells 
or from embryos using the NucleoSpin RNA II Kit (Clontech) according 
to the manufacturer’s instructions. Reverse transcription was performed 
with random primers using the RETROScript Kit (Ambion). Quantitative 
PCR was performed with TaqMan assays (Applied Biosystems) for human 
CCM2, PDCD10, GAPDH, STK24, STK25, and MST4 or mouse Pdcd10 and 
Gapdh. Quantification was performed by standard curve method, and 
Figure 8
Convergence of different mechanistic pathways in common pathology. 
(A) Proposed schema for different genes acting on separate mecha-
nistic pathways, yet ultimately resulting in a common expression of 
disease. (B) Genetic studies of hypertrophic cardiomyopathy highlight 
genes that can be grouped broadly into 2 separate mechanistic path-
ways: sarcomeric proteins such as β-myosin heavy chain (MYH7), 
and metabolic genes including adenosine monophosphate-activated 
protein kinase (PRKAG2). (C) Studies of mouse development, cell 
biology, and signaling suggest that KRIT1 and CCM2 signal through 
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CCM2 and PDCD10 transcripts were normalized to GAPDH for compari-
sons. RT-PCR primers for embryonic Pdcd10 transcripts were as follows: 
primer 4F: 5′-TTCACCGAGTCCCTCCTTCG-3′; primer 7/8R: 5′-GAACA-
CATTTATTGCCTTGCCATC-3′; primer 1F: 5′-AAGTCCGTGCCTCAGTT-
GCC-3′; and primer EGFP-R: 5′-TCCTCGCCCTTGCTCACC-3′.
Immunofluorescent cell staining. Glass chamber slides (Nalge Nunc; Thermo 
Fisher) were coated with human fibronectin (Biomedical Technologies 
Inc.), and transfected cells were seeded at 50,000 cells per well. Cells were 
fixed in 4% formaldehyde and actin cytoskeleton was visualized using flu-
orescently conjugated phalloidin (Molecular Probes; Invitrogen). Images 
were obtained with an Olympus FV300 confocal microscope.
Endothelial cell vasculogenesis in 3D collagen matrices. This assay was per-
formed as previously described (9, 38).
Immunoprecipitation and Western blotting. An expressed sequence tag (EST) 
for human PDCD10 (IMAGE: 3050540) was obtained from ATCC and cloned 
into a pcDNA3.1 Hygro+ plasmid (Invitrogen) modified to encode an N-ter-
minal FLAG tag. ESTs for Drosophila Pdcd10 and GCKIII were obtained from 
the Drosophila Genomics Resource Center and cloned into a pcDNA3.1 
Hygro+ plasmid modified to encode an N-terminal FLAG tag (Pdcd10) or 
HA tag (GCKIII). PDCD10Δ18 constructs were made using nested PCR with 
primers designed to overlap and omit the 54 nucleotides encoding those 18 
amino acids. Plasmids were transfected into EAHY or HEK 293T cells using 
Lipofectamine 2000 (Invitrogen) according to the manufacturer’s instruc-
tions, with a reduced dosage of DNA and lipofectamine for EAHY cells. Two 
days after transfection, cells were scraped into lysis buffer (50 mM Tris-HCl at 
pH 7.5, 100 mM NaCl, 0.5% Triton X-100) supplemented with protease and 
phosphatase inhibitors and 1 mM DTT. A portion of cell lysate was retained 
as whole cell lysate and the rest precleared with normal mouse IgG conjugat-
ed to agarose beads (Santa Cruz Biotechnology Inc.) at 4°C for 1 hour, then 
incubated with anti-FLAG resin at 4°C for 2 hours. The beads were washed 3 
times with lysis buffer, and bound proteins were eluted using Laemmli sam-
ple buffer. Presence of FLAG-tagged PDCD10 proteins was detected using the 
anti-FLAG M2 antibody (Sigma-Aldrich). Presence of HA-tagged GCKIII was 
detected using an anti-HA antibody (Santa Cruz Biotechnology Inc.). Near-
infrared secondary antibodies (LI-COR Biosciences) were used to probe the 
blots, which were visualized using the Odyssey system (LI-COR Biosciences).
Rabbit polyclonal antibody against PDCD10 was from Proteintech Group. 
Rabbit antibodies against phospho-myosin light chain (Thr18/Ser19), phos-
pho-VEGFR2 (Tyr1175), total VEGFR2, phospho-PLCγ (Tyr783), total PLCγ, 
phospho-ERK1/2 (Thr202/Tyr204), and total ERK1/2 were from Cell Sig-
naling Technology. α-Actinin antibody (clone H-2) was from Santa Cruz Bio-
technology Inc. HRP-conjugated secondary antibodies were from Jackson 
ImmunoResearch. Western blots were developed using the ECL Plus Western 
blotting reagent (GE Healthcare) and Kodak Biomax MR film.
Drosophila strains. The GAL4/UAS system was used for tissue-specific 
RNAi knockdown (43). The driver used was btl-GAL4 (42), and RNAi tar-
geting constructs v109453 (against Pdcd10) (41), v106841 (against Pdcd10) 
(41), and v49559 (against GCKIII) (44) were obtained from the Vienna Dro-
sophila RNAi Center. For rescue experiments, full-length cDNAs for Dro-
sophila Pdcd10 were cloned into a pUAST transformation vector containing 
an attb site for site-specific transformation (52) provided by Carl Thummel 
(University of Utah). Transgenes were injected into docking sites VK00027 
(53) and attp0016 (52) by Genetic Services Inc., and homozygous lines were 
established by standard methods.
For cDNA rescue experiments, flies homozygous for the cDNA rescu-
ing construct on the third chromosome were crossed to a homozygous 
btl-GAL4, UAS-GFP driver line on the second chromosome to generate 
transheterozygote flies (btl-GAL4, UAS-GFP/+; UAS-Rescue/+). Males of this 
genotype were then crossed to virgin females homozygous for the RNAi 
targeting construct located on the second chromosome. GFP expression 
indicated the presence of the btl-GAL4, UAS-GFP transgenes. All of these 
larvae contain 1 copy of the RNAi targeting construct, and half also have 
the cDNA rescue transgene. Results shown used the v109453 line, which 
targets the 3′ UTR of Pdcd10. The v106841 line showed similar results.
Analysis of tracheal tube formation in Drosophila larvae. Animals were scored 
at the prewandering third instar larval stage for tracheal defects. Animals 
were graded by scoring air filling in primary sprouts emanating from the 
dorsal trunk. All primary sprouts were scored bilaterally (at least 12 per 
larva). The animals were categorized as having severe, moderate, or mild 
defects or wild-type if they had 3 or more of the following defects: (a) severe 
defects were truncations before the first bifurcation of the primary side 
branches or immediately after branching; (b) moderate defects represent-
ed gaps in air filling with filled tubes on both sides; (c) mild defects were 
loss of air filling only in the fine terminal tubes. In the event that more 
than 1 criterion was met, the more severe category was selected. If animals 
had fewer than 3 branches with a given defect, the less severe category was 
selected. Only animals with no defects were categorized as wild type.
Mouse and human experiments. All mouse experiments were approved by the 
University of Utah Institutional Animal Care and Use Committee. Human 
tissue samples were obtained with written informed consent and provided 
by Connie Lee and Amy Akers (Angioma Alliance, Norfolk, Virginia, USA) 
and Randy Jensen (University of Utah). Human experiments were approved 
by the Institutional Review Board of the University of Utah.
Statistics. For actin stress fiber content, and for in vitro lumen formation 
with GCKIII kinases, we performed ANOVA with Tukey’s post hoc analy-
sis with an α value of 0.05. For in vitro lumen formation time course for 
PDCD10, we performed statistical comparisons between treatment groups 
with a 2-tailed paired-sample t test with an α value of 0.05. For the tracheal 
tube formation rescue experiment, we performed a χ2 test for independence 
with an α value of 0.05 (degrees of freedom = 9). For CCM penetrance and 
lesion content, we performed a 2-tailed t test with an α value of 0.05.
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Supplemental Figure 1.  Knockout design for Pdcd10.  Ubiquitous deletion of Pdcd10
results in early embryonic death.  (A) Alleles of Pdcd10 are shown. The floxed allele resulting
from the targeting strategy includes loxP sites flanking exons 4-8 and places the enhanced green
fluorescent protein (EGFP) in position to splice onto exon 3 in a fusion transcript resulting from
the recombined allele.  Genotyping primers are indicated by the letters W, X, Y and Z.  (B)
Genotyping by PCR using combinations of primers W, X, Y, and Z distinguishes the possible
genotypes.  (C) The wildtype and fusion transcripts are illustrated with exons outlined. The
location of primers for RT-PCR are shown.  (D) Results of RT-PCR performed on cDNA from
embryos pooled by genotype that resulted from a mating of Pdcd10+/– vs. Pdcd10+/– mice.  (E)
Gross photos of E8.0 mouse embryos on dissection.  Wildtype is shown in (E, left panel),
Pdcd10 knockout in (E, right panel).  Even at this early stage, the knockout embryo has growth











































































































































































































































































































































































































































































Supplemental Figure 3.  siRNA effectively reduces levels of PDCD10, STK25, STK24, and
MST4.  (A) Quantitative PCR to detect PDCD10, STK25, STK24, and MST4 was performed on
cDNA made from the RNA of human endothelial cells to assess knockdown.  (B) Western blot
for PDCD10 to confirm knockdown.
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Supplemental Figure 4. Pdcd10 signals through GCKIII kinases in lumen formation. (A)
Quantification of lumen area over time for human umbilical vein endothelial cells after treatment
with PDCD10 siRNA or control siRNA directed against Luciferase. (B) Toluidine blue staining
of lumen formation assay. Lumens are shown with arrowheads. (C) Quantification of lumen area
at 24 hours for cells treated with siRNA directed against each of the GCKIII kinases or
Luciferase control (5 fields per time point in 3 independent experiments). (D)
Immunoprecipitation for HA-tagged Drosophila GCKIII using full length Drosophila Pdcd10
(DmPdcd10) or Drosophila Pdcd10 with 18 amino acid deletion (DmPdcd10∆18).  Results are
representative of 3 independent experiments.  (E) Quantification of tracheal tube lumen
formation defects in Drosophila with RNAi knockdown of Pdcd10 with or without rescue
constructs (N ≥ 64 for each genotype). Note: for rescue experiments only ~50% of all larvae
contained the corresponding rescue transgene since they were generated by mating rescue
heterozygous males (btl-GAL4, UAS-GFP/+; UAS-Rescue/+) to homozygous UAS-RNAi virgin
females. (F) Quantification of 3D endothelial cell lumen area with combinatorial knockdown of
human GCKIII kinases (5 fields per time point in 3 independent experiments).  Data indicate




































































































































































































































































































































































































































































































































































Supplemental Figure 6.  PDGFb-iCreERT2 activity is specific to the endothelium.  (A) X-gal
staining (blue) of brain from a 6 month old PDGFb-iCreERT2; Rosa26-LacZ mouse that was
given tamoxifen at birth.  (B) Close-up of the boxed area in panel (A).  (C-D) X-gal (blue) and
CD31 (brown) staining of brain from a 6 month old PDGFb-iCreERT2; Rosa26-LacZ mouse that
was given tamoxifen at birth.  (E-G) CD31 (magenta) staining of brain from a 12 day old
PDGFb-iCreER
T2
; Rosa26-ACTB-tdTomato,-EGFP mouse that was given tamoxifen at birth.
Cre activation converts ubiquitous tomato expression (not shown) to EGFP expression (green).
(H-J) Neuron-specific enolase (NSE, magenta) staining of brain from a 12 day old PDGFb-
iCreER
T2
; Rosa26-ACTB-tdTomato,-EGFP mouse that was given tamoxifen at birth.  Cre
activation converts ubiquitous tomato expression (not shown) to EGFP expression (green).  Scale
bars in (A-B) = 1 mm.  Scale bars in (C-J) = 100 µm.
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Supplemental Figure 7.  LOH of either Ccm2 or Pdcd10 results in a range of vascular
malformations.  Both mouse models of CCM exhibit the same spectrum of pathology. Both the
Pdcd10 (A, C, E, and G) and Ccm2 (B, D, F, and H) induced endothelial knockout models
develop vascular lesions that exhibit the previously described spectrum of CCM pathology.
Examples shown here include lesions consistent with solitary telangiectasias (A-B), multichannel
"pristine" caverns (C-D), complex multichannel lesions with organizing thromboses (arrows in
E-F), and multiple small caverns associated with heavy hemosiderin staining (arrowheads in G-
H).  Scale bars = 200 µm.
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Supplemental Figure 8.  Loss of Pdcd10 protein from Pdcd10 (but not Ccm2) vascular
lesions.  An antibody against Pdcd10 does not stain endothelial cells of a CCM lesion from a
Pdcd10 induced knockout mouse (upper panel) but does stain the endothelial cells of a CCM
from a Ccm2 induced knockout mouse (bottom panel).  Arrows indicate endothelial cells.  Scale
bars = 50 µm.
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Supplemental Figure 9.  Murine CCMs occur in the retinal vasculature.  Lectin stained




T2 mouse (B-C), a 7 month old Ccm2flox/+; PDGFb-iCreERT2 mouse
(D), and a 7 month old Ccm2flox/–; PDGFb-iCreERT2 mouse (E-F).  All mice were given
tamoxifen at birth.  (C) Close-up of the boxed, CCM-containing area in (B).  (F) Close-up of the
boxed, CCM-containing area in (E).  Scale bars for all panels = 1 mm, except for panel (F),
which is 500 µm.
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Supplemental Figure 10.  Neural-specific deletion of Ccm2 does not result in CCMs.  (A-F)
Histology of Ccm2flox/–; Nestin-Cre mouse brain at 6 months (A-B), 7 months (C-D), and 8
months (E-F).  Staining is Prussian blue for hemosiderin with nuclear fast red counterstain.  No
lesions are found in these brains, and no hemosiderin is apparent.  Scale bars = 1 mm.  (G) Table
comparing prevalence of CCMs in neural knockout (Nestin-Cre) vs. inducible endothelial
knockout (PDGFb-CreERT2).
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Supplemental Figure 11.  Loss of PDCD10 does not affect VEGFR2-MAPK signaling.
Western blot for VEGFR2, PLCγ, and ERK1/2 phosphorylation after stimulation of HMVECs
with 10 ng/mL VEGF for the indicated amounts of time.  ns, non-specific band.
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E12.5 2 7 9 8
P1 12 17 7 7
Supplemental Table 1.  Table showing numbers of living offspring by genotype in matings
between Pdcd10flox/flox and Pdcd10+/–; Nestin-Cre parents.
CHAPTER 4
CONCLUDING REMARKS
The findings presented in this dissertation add two major contributions.  First, I
have established a reliable animal model of human CCM disease.  This first step opens
wide the field of opportunity for exploring the natural history and pathophysiology of the
disease in vivo.  Hypotheses related to signaling mechanisms and the cellular physiology
that leads to the formation of these caverns can be directly examined in the setting of a
living organism.  This animal model also makes feasible preclinical testing of potential
therapeutics for CCM disease, be they general anti-angiogenic therapies or more
specifically targeted toward CCM pathology.  Second, I have begun mapping the intricate
cellular biology involved with the CCM proteins and their functional partners.  My
evidence suggesting that the CCM proteins are not all in a common pathway will inform
clinical decisions regarding the treatment of people with familial CCM disease.  The use
of Drosophila in my studies opens the possibility of using this powerful genetic model to
screen for proteins that cooperate with Pdcd10.  Signaling proteins and the therapies that
are targeted to them can then be validated using the mouse model of disease.
The establishment of the animal model was a major hurdle in the study of this
disease.  What remains, however, is to unravel the tangled skein of biochemistry to fully
understand the functions of the CCM proteins, and how their loss leads to the aberrant
cellular behaviors that manifest as dilated vascular caverns.  A large body of work exists
52
addressing the biochemical signaling related to CCM, implicating a wide range of
proteins, including integrins , small GTPases , MAP kinases , Wnt , Notch , VEGFR2 ,1 1 1 2 3 4
GCKIII kinases , and the orphan receptor Heg1 .  Many of these proteins already5-8 9
present attractive targets for potential therapeutics.  The many interactions implicated in
CCM are hypothesized to control many aspects of cell function, including cytoskeletal
dynamics , cell polarity , endothelial barrier function , and proliferation and10 11-13 1
apoptosis .  It now becomes a race to determine which interaction partners and which5,14,15
cellular functions are the most relevant to the disease phenotype, to fully fill in the gaps
in our understanding of CCM pathophysiology.
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